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ABSTRACT 
ADVANCED ANALYTICAL TECHNIQUES FOR THE ANALYSIS OF 




Toxic inhalation agents (TIAs), (i.e., cyanide (CN) and reduced sulfur compounds 
(RSCs)), including hydrogen sulfide (H2S) and methanethiol (MT)) are extremely 
poisonous upon exposure. Many TIAs act by inhibiting mitochondrial cytochrome c 
oxidase, resulting in cellular hypoxia, cytotoxic anoxia, apnea, respiratory failure, 
cardiovascular collapse, seizure and potentially death. CN is generated in structural fires 
and cigarette smoke as well as in mining, electroplating and polymer processing, whereas 
H2S and MT are found in petroleum, oil and natural gas, waste treatment facilities and 
decaying organic matter. All are common occupational gas exposure hazards in chemical 
industries and for first responders, including firefighters, and can be used as suicide, 
homicide, or chemical warfare agents. Despite many TIAs being on the potential terrorist 
threat s list and common occupational exposure hazards, there are no FDA-approved 
intramuscular or oral antidotes for these compounds which are effective in a mass-casualty 
event. Dimethyl trisulfide (DMTS) has recently gained prominence as a promising next 
generation CN antidote. DMTS converts CN to less toxic thiocyanate (SCN) forming 
dimethyl disulfide (DMDS), a relatively toxic compound as a major breakdown product. 
Another potential antidote, aminotetrazole cobinamide (CbiAT), which is a prodrug of 
xvii 
 
cobinamide (Cbi), can directly bind and detoxify CN, H2S and MT. Both DMTS and 
CbiAT have significant advantages over current treatments, but there is no method 
available for the analysis of CbiAT in any biological matrices and the methods available 
for DMDS and DMTS analysis have significant disadvantages. Hence, in this study, an 
extremely simple and rapid dynamic headspace (DHS) gas chromatography mass 
spectroscopy (GC-MS) method was developed for the analysis of DMTS and DMDS from 
whole blood. The dynamic ranges for DMTS (0.2   
were wide and the limits of detection (LODs) (40 and 30 nM, respectively) were excellent. 
Inter- and intraassay accuracies were within 100±15%, and the precision of <10% relative 
standard deviation RSD) was excellent. The method performed well during 
pharmacokinetic analysis of DMTS and DMDS from the blood treated with DMTS. 
Although preliminary, pharmacokinetic results from DMTS-treated rats showed 
impressive results, i.e., Cmax and tmax of 0.89±0.09 M and 10 min, respectively, indicating 
rapid absorption and distribution of DMTS as well as slow elimination (t1/2 = 10.5 hr). The 
DMDS method was used to analyze the level of formation of DMDS in swine blood after 
DMTS treatment and found almost 50% conversion of DMTS to DMDS, which indicated 
about 6.7 times lower blood DMDS concentration than its LD50 value (i.e., 33.7 mg/kg). 
Understanding the level of formation of DMDS along with the availability of the methods 
will allow the further development of DMTS as a potential CN countermeasure. 
Additionally, a liquid chromatography tandem mass spectrometry (LC-MS/MS) method 
was developed for the analysis of CbiAT in plasma. The method produced an LOD of 0.3 
de dynamic range from 2  - and intraassay accuracies 
(100±12% and 100±19%, respectively) and precision (<12% and <9% RSD, respectively) 
xviii 
 
were good. The developed method was used to analyze CbiAT from treated swine and the 
preliminary pharmacokinetic parameters showed impressive results, most notably quick 
absorption, and distribution (Cmax and tmax of 44.7 µM and 4 h, respectively) and slow 
elimination (t1/2 = 23.7 h). This method can be used for the further development of CbiAT 
as a potential antidote for CN, H2S and MT poisoning. Overall, multiple methods were 
developed and validated for the analysis of CN, H2S and MT countermeasures in biological 
matrices that have significant advantages over current analytical approaches and can be 
used to perform DMTS and CbiAT drug development studies. 
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Chapter 1. Introduction 
1.1. Overall Significance 
Cyanide (CN  and HCN, inclusively represented as CN) and reduced sulfur 
compounds (RSCs, i.e., hydrogen sulfide (H2S) and methanethiol (MT)), each known as a 
toxic inhalation agent (TIA), are widely used in chemical, pharmaceutical, polymer and 
agrochemical industries. RSCs are also found in nature, including in hot springs and 
volcanoes. They are a common cause of occupational gas exposure hazards and are also 
used as chemical warfare agents or potential terrorist agents. Exposure to these agents can 
cause serious risk to human health (i.e., hypoxia, cytotoxic anoxia, cardiac arrhythmias, 
bronchospasm, respiratory paralysis, coma, and death) and the environment. There is no 
approved antidote for RSCs and approved antidotes for CN poisoning have serious 
limitations. Therefore, there is a critical need to develop novel therapeutics, which each 
require highly sensitive analytical methods for pharmacokinetic and toxicokinetic 
investigations. 
 
1.2. Project Objectives 
This research work covers three main objectives: 1) analysis of potential cyanide 
antidote, dimethyl trisulfide, in whole blood by dynamic headspace gas chromatography
mass spectroscopy, 2) analysis of the soil fumigant, dimethyl disulfide, in swine blood by 
dynamic headspace gas chromatography mass spectroscopy, and 3) analysis of 
aminotetrazole cobinamide, a next-generation antidote for cyanide, hydrogen sulfide and 
methanethiol poisoning, in swine plasma by liquid chromatography-tandem mass 
spectrometry. Chapter 2 describes a rapid and highly sensitive gas chromatography mass 
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spectroscopy (GC-MS) method for a highly promising next generation CN antidote, 
dimethyl trisulfide (DMTS), in blood and preliminary pharmacokinetic profile of DMTS 
in rat blood. Chapter 3 addresses a GC-MS method for a relatively toxic soil fumigant and 
the major breakdown product of DMTS, dimethyl disulfide (DMDS), and preliminary 
correlation between the formation of DMDS in blood following DMTS administration. 
Chapter 4 focuses on determination of aminotetrazole cobinamide (CbiAT), which is 
effective against CN, H2S and MT poisoning and the analysis of the compound in swine 
plasma obtained from a CbiAT pharmacokinetic study. Chapter 5 describes conclusions, 
broader impacts and suggested future works. 
 
1.3. Toxic Inhalation Agents  
The most common route of toxic exposure is inhalation, although it can happen via 
ingestion or direct skin or eye contact [1]. Inhalation of toxic gases and vapors as well as 
liquids or solids in the form of mists and aerosols can directly affect respiratory tract 
resulting in irritation, bronchiolitis, and pulmonary edema, and in severe cases, they may 
cause systemic toxicity [1, 2]. Toxic inhalation agents (TIAs) are gases and vapors that are 
detrimental to health and can be deadly when someone is exposed. Examples of TIAs 
include CN, H2S, MT, mustard gas, sarin, cyclosarin, nerve gas, ammonia, phosgene, 
diphosgene, carbon monoxide, methyl isocyanate, methane, formaldehyde, ozone, chorine, 
hydrogen chloride, and hydrogen fluoride [2, 3]. Exposure to these chemicals can happen 
in several ways, but because of industrialization, the most common cause is occupational 
exposure where mishandling of chemicals, inadequate ventilation or improper protective 
equipment is the root cause of fatalities in chemical, pharmaceutical or plastic industries 
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[1]. Other major sources of exposure are: (1) structural fire smoke, which typically contains 
carbon monoxide and HCN, (2) mixing of household chemicals or gas leakage (i.e., 
methane or carbon monoxide exposure), and (3) acts of terrorism using TIAs, e.g., 
phosgene, CN, H2S, MT, chlorine, nerve agents and sulfur mustard) [1, 2, 4]. Because of 
their ease of production, low manufacturing cost and high reactivity, TIAs are commonly 
used in chemical industries for the synthesis of many compounds of pharmaceutical and 
agricultural importance. These are also used for the production of plastics, synthetic fibers 
and polymers, gold mining, insecticides, antiseptics, and dyes and pigments [5].   
The demand for TIAs is increasing worldwide, therefore, industrial, mining 
workers, and custodians are frequently becoming the victims of these chemicals. Fatalities 
have been reported almost every year because of the accidental leakage of TIAs in 
industries and densely populated areas, and even unregulated storage and transportation 
have also been playing role for many mass-casualties [6-9]. There are many incidences 
where military groups have deliberately released TIAs on the battlefields to kill and injured 
adversary troops [10]. In 1984, a major industrial disasters occurred in Bhopal, India, where 
isocyanate from explosion resulting from a leak in a storage tank [6, 11]. There are many 
historical incidents of exposure to TIAs other than inhalation. For example, the Jonestown 
massacre, in Guyana in 1978, resulted in the death of more than 900 people, including 
children, because of toxic CN ingestion [12]. Moreover, the first large-scale incidence of 
chemical terrorism or product tampering happened in the mainland of the U.S. in 1982 in 
Chicago, where seven people died by consumption of CN-laced Tylenol [13]. The 
4 
 
perpetrator collected the drugs from the store, added CN (60-100 mg per capsule) and put 
them back to the store [14].  
 
1.4. Pathogenesis of TIAs 
Exposure to TIAs (e.g., CN, H2S or MT) can cause mild to severe damage to the 
respiratory tract depending on the level and duration of exposure, particle size and the water 
solubility of the TIA [1, 15]. Highly water soluble TIAs with comparatively greater particle 
size (>10 µm) generally deposit in the upper respiratory tract, whereas low solubility gases 
or small-sized particles (<5 µm) reach the lower part of the respiratory tract (Figure 1.1).  
 
 
Figure 1.1. Aqueous solubility and particle size-based site of injury of TIAs in the 
respiratory tract [1]. 
 
response, metabolic rate, smoking history, condition of the lungs, immune response and 
High water solubility and irritative 
(e.g., cyanide, ammonia, formaldehyde, 
hydrogen chloride, hydrogen fluoride) 
Intermediate water solubility 
(e.g., chlorine) 
Low water solubility and less irritative 
(e.g., phosgene, mustard gas, ozone) 
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underlying disease [1, 16]. Mild level of exposure of TIAs generally creates watery eye, 
sneezing, coughing and mucous membrane irritation, whereas in prolong or severe case, it 
can severely damage lungs by causing pulmonary edema and asphyxiation. Even, entering 
into the systemic circulation, they can terminate the oxidative phosphorylation process 
binding with cytochrome c oxidase, and causing cellular hypoxia, cardiac arrest, and even 
death in some cases [16-19]. 
 
1.5. Exposure to CN, H2S, and MT 
Exposure to CN, H2S and MT can occur by inhalation, ingestion, or skin 
penetration. Once absorbed, these compounds exhibit very similar mechanisms of toxicity, 
therefore, they produce almost identical clinical signs and symptoms. After entering into 
the systemic circulation, they distribute throughout the body quickly, bind strongly with 
cytochrome c oxidase, and terminate the oxidative phosphorylation process [17, 20-22]. 
As a result, cytochrome c oxidase loses the ability to carry oxygen in the body, thereby 
disrupting electron transport chain, increasing cellular lactic acid concentration, lowering 
ATP production, and producing cellular hypoxia, hyperlactatemia, metabolic acidosis, 
cytotoxic anoxia, cardiac arrest and even death [7, 23-25]. These compounds can inhibit 
many other vital enzymes, including succinic dehydrogenase, superoxide dismutase and 
carbonic anhydrase, therefore inhibiting the formation of fumarate in the Krebs cycle, 
blocking the removal of harmful reactive oxygen species (ROS) and interrupting the 




1.6. Hydrogen Cyanide 
1.6.1. Overview 
Hydrogen cyanide (HCN), also known as hydrocyanic acid and prussic acid, is an 
extremely poisonous chemicals (human LD50, 30-min inhalation = 150-173 ppm) [10]. It 
is lighter than air (density = 0.94), and has a boiling point of 26 °C.  It is a relatively weak 
acid, with a pKa of 9.32, and is soluble in water, chloroform and ethanol [28]. 
 
1.6.2. Sources and use of CN 
CN can be found in nature and is produced by fungi, bacteria, and plants [29]. It 
can also be produced by volcanic eruption [29], but the major sources of natural CN are 
cyanogenic plants, which include cassava, apples, almonds, peaches, and apricots [29-32]. 
Among these, cassava, a staple food in Africa, contains highest percentage of CN (i.e., 1
1550 ppm in root, 900-2000 ppm in the peel and 20 1860 ppm in the leaves) [33]. CN can 
also be produced from anthropogenic sources, including mining, electroplating and 
polymer processing, and from burning of anthropogenic materials, (e.g., cigarettes, rubber, 
fibers, etc.) [34, 35]. 
 CN is extensively used for the extraction of various metals (e.g., gold, silver, and 
zinc) from the soil or rocks [17, 36]. Current annual industrial need of CN is over 1.1 
million tons [17]. Other industrial uses include production of polymers, fabrication of 




1.6.3. Major CN exposure events 
Because of low production cost, ease of synthesis and high toxicity, many casualties 
have been reported related to CN. A few of them are reported here. The Holocaust, a mass 
murder of Jews during 1941-1945 under the regime of Nazi, was performed in gas 
chambers by applying Zyklon B, which contains HCN gas. This brutal and deadliest event 
killed roughly one million Jews people [39, 40].  The mass-suicide event, Jonestown 
massacre, was happened in Guyana on November 18, 1978, where a group of followers 
(including over 300 children) of a cult leader, Jim Jones, drank CN-laced fruit punch. This 
so-
mass-casualty events in American history [12, 41]. In Tianjin, China in 2015, a warehouse 
containing sodium cyanide (700 tons) was exploded and caused the death of 115 people. 
Because of this explosion, the surrounding CN level was increased as high as 365 times 
greater than the normal safety margin. This incidence also contaminated the river water 
and caused the death of thousands of fishes [42, 43].  
 
1.6.4. Current treatments and limitations 
Three U.S. Food and Drug Administration (FDA)-antidotes are currently available 
to detoxify CN: sodium nitrite (methemoglobin/nitric oxide generator), hydroxocobalamin 
(direct binding agent), and sodium thiosulfate (sulfur donor). These antidotes are 
commercially available as two intravenous (IV) drugs: Nithiodote® (a preparation of 
sodium thiosulfate and sodium nitrite mixture) and Cyanokit® (contains 




1.6.4.1. Sodium nitrite 
Sodium nitrite is commercially available as Nithiodote® in combination with the 
sulfur donor, sodium thiosulfate, in the form of an IV preparation. It is a sterile solution 
containing 300 mg of sodium nitrite in a 10-mL glass vial and administered at a rate of 2.5-
5 mL/min. Depending on the severity of exposure, a second dose (150 mg of sodium nitrite) 
is recommended at the same rate [44]. Sodium nitrite antagonizes CN poisoning via two 
routes: (1) indirect sequestering by generating methemoglobin, and (2) direct displacement 
by forming nitric oxide (NO) [45]. Indirect sequestering involves oxidation of Fe2+ to Fe3+ 
in hemoglobin, resulting in the formation of methemoglobin, which has a relatively strong 
affinity towards CN. By replacing the hydroxyl group at position 6 of the iron in 
hemoglobin, methemoglobin binds CN to form the less toxic cyanomethemoglobin and 
excretes this product by the regular body process [24, 45, 46]. Additionally, sodium nitrite 
can directly displace CN from cytochrome c oxidase by undergoing biotransformation to 
form NO [47].  But the major limitation is that the production of methemoglobin limits the 
oxygen carrying capacity and excess production of methemoglobin (>30%) causes 
additional health hazards, including headache, fatigue, cyanosis, hypotension, coma, and 
even death. It is not recommended and can be lethal for smoke-inhalation victims with high 
carboxyhemoglobin (<10%), as it reduces oxygen-carrying capacity of the blood [24]. 
Therefore, following sodium nitrite treatment, patients may need to be treated with 
supplemental oxygen and methylene blue to convert methemoglobin back to hemoglobin 




1.6.4.2. Sodium thiosulfate 
Sodium thiosulfate, a sulfur donor, converts CN to less toxic thiocyanate (SCN) by 
donating one sulfur to CN. This conversion requires rhodanese, a mitochondrial thiosulfate 
sulfurtransferase enzyme [50, 51]. Although, it is safer than sodium nitrite and is readily 
excreted from the body, its sulfur donating capability depends on less available rhodanese 
and its inability to quickly transverse cell walls cause delayed onset of action. Some organs, 
including brain and heart, have no (or very low) available rhodanese, therefore, the CN 
detoxification process problematic in these organs, if sodium thiosulfate is administered 
alone [24]. It is commercially available as an IV preparation (12.5 g/50 mL vial) and must 
be administered via IV over a 10-min period following sodium nitrite administration [44]. 
A second dose of sodium thiosulfate (6.25 g) is sometimes required 
condition. Apart from rhodanese dependency, it has short biological half-life and requires 
trained medical stuff for administrating the drug [44, 52].  
 
1.6.4.3. Hydroxocobalamin 
Hydroxocobalamin (available as Cyanokit®) binds directly with CN and forms a 
much less toxic and water-soluble cyanocobalamin (vitamin B12). The central cobalt ion 
(Co3+) of hydroxocobalamin has a strong affinity for CN, which replaces the hydroxyl 
ligand attached to it [53, 54]. Hydroxocobalamin also requires IV infusion, and has a large 
recommended dose (5 g over 15 min at a rate of 15 mL/min). Like Nithiodote®, it also 
requires the support from medical personnel to administer. Although it is safe, it requires 
on-site reconstitution and is expensive [44, 45]. A second dose is also recommended over 
a prolonged period (15 min to 2 h) for patients with severe CN poisoning [50]. 
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Although the current FDA-approved CN antidotes are effective, but each has major 
limitations. Both antidotes require slow IV infusion, which necessitates the help from a 
trained medical stuff [55, 56]. They require large dose, expensive, and depending on the 
level of exposure, a second dose is sometimes required [44, 57]. They may cause adverse 
effects, including dizziness, vomiting, confusion, hypotension, hypertension, cardiac 
arrythmia, and methemoglobinemia and require special medical supervision [57-59]. 
 
1.7. Hydrogen Sulfide 
1.7.1. Sources and Applications 
H2S is a colorless, corrosive, and flammable compound. It occurs naturally in 
decaying organic matter, natural gas, petroleum, waste water treatment facilities and 
volcanoes [60]. It is a weak acid with a pKa of 6.9, dissolves in water to form hydrosulfide 
(HS-) [61]. It is commonly used in chemical industries as a source of elemental sulfur for 
the synthesis of MT, ethanethiol and thioglycolic acid. It is also used in the pulp and paper 
industries to break down cellulose and lignin components [62].  
 
1.7.2. Toxicity 
H2S is a highly toxic compound and the second most common cause of occupational 
gas exposure hazard [22]. The LC50-value of H2S in rats is 444 ppm for 5-min of inhalation 
exposure [55]. Common sulfur-containing household items can produce toxic levels of H2S 
when mixing with acid cleaner, which can be lethal in a small or enclosed room [63-65]. 
Brief or low-dose exposure to H2S can cause several health problems, including fatigue, 
eye irritation, memory loss, dizziness and loss of appetite, whereas prolonged or high-dose 
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exposure can induce immediate collapse, respiratory paralysis, and even death [66]. 
Although H2S poses occupational, environmental, and even chemical threat, there is no 
currently-approved FDA approved antidote available for H2S poisoning [22]. 
 
1.7.3. Recent H2S exposure events 
Many incidences and fatalities happened because of the H2S exposure in an 
unregulated industrial setting, including poor chemical handling and inadequate 
ventilation. Suicide by inhaling H2S is not that rare also [67]. An article published in 2010 
[67], focused on the suicidal craze of Japanese people using homemade H2S, reported the 
deaths of 208 individuals between March to June in 2008.  Most of the cases were happened 
when bath additive (containing lime sulfur) was mixed with toilet detergent, which 
generated toxic H2S gas. 
 
1.8. Methanethiol 
1.8.1. Sources and Applications 
MT, also known as methyl mercaptan, is a flammable, colorless gas and has a 
characteristic rotten cabbage odor. It has a low boiling point (6 °C) and is heavier than air, 
with a density of 1.66 (air = 1), therefore, it is mostly found in low-lying regions [68]. MT 
is also detected in the air around the waste treatment facilities, including sewage plants and 
landfills [68, 69]. It is added to natural gases to detect gas leakage, and is used in chemical 
industries to produce methionine, which is a dietary component of animal food, and for the 
manufacturing of pesticides [68, 70]. It is found in high concentrations in waste treatment 
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facilities, and also generated in paper, pulp, plastic, and petroleum industries as a waste 
product [69].  
 
1.8.2. Toxicity 
Although MT has many industrial applications, it is highly poisonous, with a LC50 
value in rats for 5-min of inhalation exposure of 675 ppm [71]. Prolonged and high 
concentration exposure to MT can lead to dizziness, vomiting, fatigue, bronchospasm, air 
flow obstruction, asthma, ischemic heart disease, hypotension, pulmonary and central 
nervous system damage, coma and even death [72-75]. Although mass exposure to MT in 
an industrial setting remains an ongoing risk, the Department of Homeland Security has 
stablished a safe handling practice guideline for MT and the Occupational Safety and 
Health Administration (OSHA) has proposed an emergency response guideline for MT, 
yet there is no-FDA approved antidote available for MT poisoning [68, 69]. 
 
1.9. Potential Antidotes Against CN, H2S and MT Poisoning 
No treatment currently exists for H2S and MT poisoning, but there are multiple CN 
antidotes. While these antidotes can be effective, they each have limitations. The 
limitations of current antidotes limit their applicability in a mass-casualty event (i.e., 
industrial accident, structural fire, or terrorism), where quick treatment of CN poisoning is 
extremely vital [57, 76]. These limitations have necessitated the search for superior 
countermeasures which are effective via oral or intramuscular (IM) route by untrained 
personnel. Recently, four antidotes (i.e., dimethyl trisulfide, cobinamide, 3-
mercaptopyruvate and sodium tetrathionate) show promising results in overcoming the the 
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limitations of current CN antidotes. Among these, dimethyl trisulfide (DMTS) and 3-
mercaptopyruvate (3-MP) are effective against CN [17, 77], sodium tetrathionate (STT) is 
effective against both CN and MT [76], and cobinamide (in the form of aminotetrazole 
cobinamide, CbiAT) can detoxify each of these poisons [22].  
 
1.9.1. Dimethyl trisulfide 
DMTS, a promising next generation sulfur donor, has proved very effective against 
CN toxicity [23, 78, 79]. DMTS converts CN to less toxic SCN and forms dimethyl 
disulfide (DMDS) as a breakdown product [36]. Unlike current FDA-approved sulfur 
donor, sodium thiosulfate, it does not require the active presence of rhodanese enzyme, is 
79 times more effective, and can be administered IM [80]. In presence of rhodanese, it 
shows 43 times better antidotal properties than sodium thiosulfate [17]. It is highly 
lipophilic and can easily cross blood brain barrier and cell membranes [45]. Recent studies 
have shown that DMTS is about 3 times superior to sodium thiosulfate at detoxifying CN 
[80]. Figure 1.2 shows the reaction of DMTS with CN to detoxify CN, in presence or 














Figure 1.2. Reaction showing the conversion of CN to SCN and the formation of DMDS 
as a byproduct of this reaction. 
 
1.9.2. 3-Mercaptopyruvate 
Like sodium thiosulfate, 3-MP, is a sulfur donor and acts by donating one sulfur 
unit to CN to form the less toxic SCN [77]. The advantage of 3-MP over sodium thiosulfate 
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is that it does not depend on rhodanese, it instead is catalyzed by a more readily available 
enzyme (i.e., 3-mercaptopyruvate sulfurtransferase, 3-MST). 3-MST is available in all the 
vital organs, including heart, brain, lungs, liver, and kidney, and therefore, can better 
protect CN-exposed victims [81]. Moreover, 3-MST is available in both mitochondria and 
cytosol, whereas rhodanese is generally only found in mitochondria, allowing improved 
protection for CN intoxication [82, 83]. The disadvantages of 3-MP are poor bioavailability 
and instability in blood [84, 85]. Therefore, several prodrugs have been tested, among 
which the dimer of 3-MP (sulfanegen) has shown promising results [85, 86]. This dimer is 
soluble in water and nonenzymatically breaks down into two 3-MP molecules under 
biological conditions, making it a promising drug candidate for treating CN poisoning [86]. 























Figure 1.3. Reaction showing the formation of nontoxic SCN from CN by the donation 
of singlet sulfur from the 3-MP molecule. 
 
1.9.3 Sodium tetrathionate 
STT is a highly water-soluble compound, which can detoxify two CN molecules 
via a two-step reaction. The first step involves the direct reaction of STT with CN (known 
 This direct interaction produces sodium thiosulfate, which 




action makes STT 1.5 to 3.3 times more effective than sodium thiosulfate at detoxifying 
CN [76, 88]. Figure 1.4 shows the two step CN detoxification process of STT. 
 
Na2S4O6                                              Na2S2O3                                           SO32- 
 
Figure 1.4. A two-step reaction of STT with 2 moles of CN. 
 
Based on a recent study [76], STT was found to be well-tolerated by rats, mice and 
rabbits via IM injection and it effectively neutralized sodium cyanide. Moreover, STT 
rescued mice from a lethal MT gas exposure. Although, STT seems to be a promising drug 
candidate for both CN and MT poisoning, but only a few animal experiment [76, 89] have 
been performed on STT, therefore, more animal experiment need to be done to elucidate 
its bioavailability, safety and effectiveness. 
 
1.9.4 Cobinamide 
Cbi (available as Cyanokit®), a vitamin B12 analogue and the penultimate precursor 
of hydroxocobalamin biosynthesis. It has recently gained attention for its capability in 
treating multiple metabolic poisons, including CN, H2S and MT [22, 90-95]. Although its 
structure is similar to hydroxocobalamin, unlike hydroxocobalamin, it has two ligand 
binding sites instead of one. This makes it more effective than hydroxocobalamin [22]. 
Moreover, Cbi shows much higher affinity for ligands than hydroxocobalamin because it 
does not suffer from the negative trans effect of dimethyl-benzimidazole group on the 
upper binding site [55, 96]. As a result, it requires 3-10 times less Cbi dose than 
hydroxocobalamin to produce similar antidotal efficacy [56, 91]. In aqueous solution, Cbi 
is predominately present as aquohydroxocobinamide (AHCbi, [Cbi(OH)(H2O)]+), but 





under acidic and basic conditions, it can also present as diaquocobinamide ([Cbi(H2O)2]2+) 
and dihydroxocobinamide ([Cbi(OH)2]), respectively [56]. Although, AHCbi has five 
times greater water solubility than hydroxocobalamin [96], it is not a good drug candidate 
for IM administration because it interacts with the macromolecules in the extracellular 
matrix (ECM) at the injection site, which limits its rate of absorption post-injection [97]. 
Recently, a prodrug of Cbi, aminotetrazole cobinamide (CbiAT), has shown very 
promising results for treating CN, H2S and MT poisoning. It is safe and highly potent, 
allowing for quick absorption after IM administration, and effective binding of CN, H2S 
and MT [22, 68, 95]. Figure 1.5 shows the reaction between CbiAT and CN, where one 
molecule of CbiAT detoxifies two molecules of CN. A similar mechanism is responsible 














































































CbiAT  Cbi(CN)2 
Figure 1.5. Reaction showing the interaction between CbiAT and CN, where the central 







Chapter 2. Analysis of Potential Cyanide Antidote, Dimethyl Trisulfide, in Whole 
Blood by Dynamic Headspace Gas Chromatography-Mass Spectroscopy 
 
2.1. Abstract 
Cyanide is a rapidly acting and highly toxic chemical. It inhibits cytochrome c 
oxidase in the mitochondrial electron transport chain, resulting in cellular hypoxia, 
cytotoxic anoxia and even death. In order to overcome challenges associated with current 
cyanide antidotes, dimethyl trisulfide (DMTS), which converts cyanide to less toxic 
thiocyanate in vivo, has gained much attention recently as a promising next-generation 
cyanide antidote. While there are three analysis methods available for DMTS, they each 
have significant disadvantages. Hence, in this study, a dynamic headspace (DHS) gas 
chromatography mass spectroscopy method was developed for the analysis of DMTS from 
rabbit whole blood. The method is extremely simple, involving only acidification of a 
blood sample, addition of an internal standard (DMTS-d6) and DHS-GC-MS analysis. The 
method produced a limit of detection of 0.04 µM for DMTS with dynamic range from 0.2-
50 µM. Inter- and intraassay accuracy (100±15% and 100±9%, respectively), and precision 
(<10% and <9% relative standard deviation, respectively) were good. The validated 
method performed well during pharmacokinetic analysis of DMTS from the blood of rats 
treated with DMTS, producing excellent pharmacokinetic parameters for the treatment of 
cyanide exposure. The method produced significant advantages over current methods for 
analysis of DMTS and should be considered as a  method for the further 





Hydrogen cyanide (HCN) is an extremely poisonous chemical with a human LD50 
of only 150-173 ppm via inhalation for a 30-min exposure. Because of its toxicity, HCN 
has been used as a chemical warfare agent, but it is more commonly found in smoke from 
cigarettes or fires and in food items [23, 24, 37]. Despite its serious health and safety related 
concerns, both forms of cyanide (HCN and CN-, inclusively represented as CN) are widely 
used in the chemical industry to produce polymers, to fabricate synthetic fibers, for 
electrolysis, to extract minerals, for electroplating, and for pest control [7, 37, 38]. Because 
of its industrial uses, the approximate global industrial need for cyanide is 1.1 million tons 
per year [7]. Cyanide exposure can occur through inhalation, ingestion and absorption 
through the skin. Once CN is absorbed, it quickly distributes throughout the body and 
moves through cells to strongly bind with cytochrome C oxidase. CN blocks the ability of 
oxygen to bind to cytochrome C oxidase, thereby terminating oxidative phosphorylation. 
As a result, glycolysis becomes the preferred method of energy production, increasing the 
lactic acid concentration in cells, resulting in metabolic acidosis.  As a result, the toxic 
outcomes of CN poisoning include cellular hypoxia, cytotoxic anoxia, cardiac arrest, and 
death [7, 23-25]. 
Three antidotes have commonly been used to treat cyanide poisoning: sodium 
nitrite (methemoglobin/nitric oxide generator), hydroxocobalamin (direct binding agent), 
and sodium thiosulfate (sulfur donor). They are commercially available as Cyanokit® 
(hydroxocobalamin) and Nithiodote® (the combination of sodium thiosulfate and sodium 
nitrite), and both are administered intravenously (IV). Hydroxocobalamin has a strong 
affinity towards cyanide, binding it to form cyanocobalamin (Vitamin B12), which is water 
19 
 
soluble and readily excreted from the body [45]. Although hydroxocobalamin has a rapid 
onset of action and is generally considered safe, it has some limitations. It requires on-site 
reconstitution, is expensive, and has a large recommended dose (5 g administered by IV 
infusion over 15 min). It also must be administered at a rate of approximately 15 mL/min 
by trained personnel, which limits its acceptability in mass-exposure situations. Moreover, 
a second dose of 5 g is sometimes required over a prolonged period (15 min to 2 h) 
depending upon the severity of poisoning [44, 45, 50]. 
Sodium nitrite, which is often used in combination with sodium thiosulfate, 
antagonizes CN activity by generating methemoglobin and by forming nitric oxide (NO). 
It oxidizes Fe2+ to Fe3+ in hemoglobin to form methemoglobin. Methemoglobin has a 
strong affinity to cyanide and serves as a temporary binding site. Methemoglobin then 
transiently removes free cyanide as cyanomethemoglobin [24, 45]. Although 
methemoglobin 
also undergo biotransformation to form NO, which can directly displace CN from 
cytochrome c oxidase, and reverse its toxicity [47].  Sodium nitrite is commercially 
available for IV administration (300 mg/10 mL vial at a rate of 2.5-5 mL/min) in 
combination with sodium thiosulfate (Nithiodote®), with a second dose (150 mg at a rate 
of 2.5-5 mL/min) potentially required, depending upon the severity of poisoning [44]. 
Unlike hemoglobin, methemoglobin cannot carry oxygen and its excess production (>30%) 
leads to headaches, cyanosis, fatigue, coma, and death in severe cases. Moreover, it causes 
hypotension and should not be used for smoke-inhalation patients with high 
carboxyhemoglobin (<10%) [24], which also reduces the oxygen-carrying capacity of 
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blood. Therefore, supplemental oxygen and methylene blue may also be administered to 
convert methemoglobin back to hemoglobin, following nitrite administration [24, 48, 49]. 
Sodium thiosulfate converts cyanide to less toxic thiocyanate in presence of 
rhodanese (a mitochondrial thiosulfate sulfurtransferase enzyme). The thiocyanate is 
subsequently excreted in urine [50, 51]. Although, sodium thiosulfate is safer than sodium 
nitrite, it has a delayed onset of action. Therefore, it is administered with sodium nitrite as 
Nithiodote® to overcome this limitation [24]. It is administered intravenously (12.5 g/50 
mL vial) and requires a large dose (12.5 g administered by IV infusion over 10 min) 
immediately following the administration of sodium nitrite, with a second dose of 6.25 g 
potentially required [44]. Like hydroxocobalamin and sodium nitrite, trained medical 
personnel are necessary for administration, which limits the use of sodium thiosulfate in 
mass casualty cyanide-poisoning events. 
The limitations of currently available antidotes have necessitated the search for 
next-generation CN antidotes. Recently, dimethyl trisulfide (DMTS) has shown impressive 
efficacy against cyanide toxicity and has other advantages over current treatments [23, 78, 
79]. DMTS, which is found in some whole and processed foods (e.g., garlic and soy sauce), 
converts cyanide to thiocyanate and is 43 times more effective than thiosulfate in presence 
of rhodanese [45, 98-102]. In the absence of rhodanese, DMTS shows even higher relative 
efficacy (79 times) [45]. Animal studies have shown that DMTS is up to 3 times more 
effective at treating CN poisoning than sodium thiosulfate, as measured by antidotal 
potency ratio (APR) [80]. Because it is less dependent on rhodanese and has higher cell 
membrane permeability than thiosulfate, DMTS promises to be more effective as a sulfur 
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donor. It can also be administered intramuscularly (IM), which allows feasible use in a 
mass-casualty scenario [103]. 
Three methods of analysis of DMTS from biological samples have been published, 
including stir bar sorptive extraction (SBSE) GC-MS [45], headspace solid-phase 
microextraction (HS-SPME) GC-MS, and HPLC-UV techniques [104]. Although these 
methods are effective, each approach has significant disadvantages. The SBSE method 
features simple acidification of blood, extraction of DMTS via an SBSE stir bar, and 
analysis of the stir bar via thermal desorption GC-MS. While it is highly sensitive (LOD = 
0.06 µM), this method does have the disadvantages of requiring sorptive stir bars to extract 
DMTS from the blood matrix, making it a relatively costly technique (even though the stir 
bars can be reused multiple times) and the sample preparation is relatively lengthy. The 
HPLC-UV method involves defibrinating blood, addition of DMDS (used as IS), 
precipitation of blood proteins by centrifugation (14,000  × g at 4°C for 5 min), and analysis 
of supernatant by HPLC using C8 column and a UV detector at 215 nm. While this 
technique has the advantage of more straightforward and affordable sample preparation, it 
is 193 times less sensitive than the SBSE technique, with a reported LOD of approximately 
11.56 µM (reported as 1.46 µg/mL). Also, DMTS is converted to DMDS during its reaction 
with cyanide, so it should not be used as an IS in DMTS-treated and cyanide-exposed 
individuals. For increased sensitivity, the same authors used an SPME technique which 
featured homogenized brain samples (in aqueous polysorbate 80 or HPLC grade ethanol), 
extraction of DMTS via direct immersion SPME with a polydimethylsiloxane (PDMS) 
sorbent, and analysis via GC-MS. While the reported LOD (213 ng/g of brain, which is 
1.49 µM) is much lower than the HPLC method, it is still about 25 times less-sensitive than 
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the SBSE technique. Additionally, similar to SBSE, SPME requires relatively expensive 
microextraction components. To overcome the limitations of current DMTS analysis 
methods, there is a need to develop a simple, sensitive, and less costly technique to analyze 
DMTS from whole blood.  
Therefore, the objective of this study was to develop and validate a simple and 
effective DHS-GC-MS method for the detection of DMTS in rabbit whole blood which 
combines the advantages of each of previous published methods. The availability of such 
a method would accelerate further development of DMTS as a possible next-generation 
cyanide antidote. 
 
2.3. Experimental   
2.3.1. Materials 
All reagents and solvents were of reagent grade unless mentioned otherwise. 
Methanol (LC-MS grade) and sulfuric acid (certified ACS plus) were purchased from 
Fisher Scientific (Fair Lawn, NJ, USA).  Reverse-osmosis water was passed through a 
polishing unit (Lab Pro, Labconco, Kansas City, KS, USA) and had a resistivity of 18.2 
-cm. DMTS and internal standard (IS) dimethyl-d6 trisulfide (DMTS-d6) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA) and US Biological Life Sciences 
(Salem, MA, USA), respectively. Freshly prepared DMTS stock solution in methanol (200 
mM) was used for each experiment and the standard DMTS container was kept in the dark 
at ambient temperature. The as received IS solution was diluted in methanol to produce a 
stock solution of 100 mM, which was further diluted to 1 mM in DI water and stored in -
30 °C freezer (Isotemp plus freezer, Fisher Scientific, NJ, USA). Thermal desorption tubes 
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filled with Tenax® TA sorptive material, was obtained from Gerstel Inc. (Linthicum, MD, 
USA). The sorbent was conditioned using a TC 2 tube conditioner and Aux-controller 163 
(Gerstel Inc., MD, USA) for 8 h at 315 °C under 68 psi of ultra-high purity (UHP) 5.0 
grade nitrogen gas (A-OX Welding Supply Co., Sioux Falls, SD, USA) before use for the 
first time. One TD tube was used for the entirety of the current study. 
 
2.3.2. Biological samples 
Rabbit whole blood (Non-sterile with EDTA), obtained from Pel-Freez Biologicals 
(Rogers, AR, USA), was used for method development and validation, and was kept in a 
TSU series, Thermo scientific, NJ, USA) until used. Following validation, 
the effectiveness of the DMTS method was evaluated by analyzing blood from a DMTS 
pharmacokinetic study performed at United States Army Medical Research Institute of 
Chemical Defense (USAMRICD, Aberdeen Proving Ground, MD, USA). Male Sprague 
Dawley® SAS-400 rats (Charles River Laboratories, Kingston, NY, USA) implanted with 
jugular vein catheters were used for this study. Rats, weighing between 250 350 g, were 
intramuscularly (IM) administered with a proprietary formulation of DMTS to the right 
caudal thigh muscle. Multiple blood draws were performed from each catheterized rat. A 
maximum of 7 blood draws for each rat were randomly distributed among the cohorts at 
times: 0 (blank control), 2, 5, 10, 15, 30, 60, 90, 120, 180, 240, 300 and 360 min. Note: 
The total maximum blood volume drawn from each rat did not exceed 700 µL. Negative 
control samples were drawn from rats prior to DMTS injection. For each sample, 50 µL of 
blood was collected into a syringe from the jugular vein catheter, and the blood samples 
Preparation of DMTS standards and samples
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The prepared samples were then flash frozen and shipped to South Dakota State University 
(Brookings, SD, USA) on dry ice for analysis. Samples were kept at 80 °C until analyzed. 
All animals were handled and housed in accordance with the Guide for the Care and Use 
of Laboratory Animals published by the United States National Institutes of Health (NIH 
Publication No. 85-23, Revised 1996). The experimental protocol was approved by 
Institutional Animal Care and Use Committee at USAMRICD. 
 
2.3.3. Preparation of DMTS standards and samples 
The stock solution of DMTS (200 mM in methanol) was diluted to 4, 10, 15, 20, 
40, 100, 150, 200, 400, 700, and 1000 µM with DI water to produce working standard 
solutions. Whenever needed, 40 µM aqueous IS was prepared from a 1 mM stock solution 
in methanol and was either added directly to acidified blood (see below) or spiked (100 
µL) into DMTS working standard solutions (1:1 mixture of DMTS:IS).  
samples where a large 
volume of blood is available, 450 µL of whole blood (i.e., rabbit blood for this study) was 
transferred to a 4-mL HPLC vial with 500 µL of 0.4% sulfuric acid. The mixture was then 
vortexed for 10 s at 252 × g to ensure proper coagulation and denaturation of proteins. Note 
that acid denaturation prior to the addition of DMTS and/or IS is a crucial step in DMTS 
sample preparation to mitigate the quick and irreproducible degradation of DMTS in non-
denatured blood. Finally, 50 µL of a DMTS:IS mixture (for standards) or an IS solution 
(for samples) was added to the acidified blood (950 µL). The sample was then vortexed for 
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10 s at 252 × g, and an aliquot of the sample solution (100 µL) was placed in a 20-mL HS 
vial with a polytetrafluoroethylene-lined septum for analysis. 
For the preparation of blood samples from the animal studies, where only a small 
volume of blood was available, 0.4% sulfuric acid (950 µL) was added to a 2-mL centrifuge 
tube along with 50 µL of whole blood (e.g., rat blood in this study) with mixing. IS (25 µL 
of 6 µM) was then added. The sample was mixed and flash frozen. For preparation of 
standards for the small volume protocol, acidified blood (25 µL) was spiked with 50 µL of 
a mixture of DMTS:IS, and then vortexed for 10 s to ensure proper mixing. An aliquot of 
this preparation (900 µL) was placed in a 20-mL HS vial for analysis.  
In both approaches, the concentrations of DMTS in the acidified blood calibration 
standards were 0.2, 0.5, 0.75, 1, 2, 5, 7.5, 10, 20, 35, and 50 µM, whereas the IS 
concentration was fixed at 2 µM (final concentration). When analyzing the whole blood of 
DMTS-treated animals, acidification and addition of the IS was performed immediately 
following the collection of blood to ensure minimal degradation of DMTS.  
 
2.3.4. DHS-GC-MS analysis of DMTS 
Analysis of prepared samples was performed using DHS via a Gerstel MPS sampler 
(Gerstel Inc., Linthicum, MD, USA) coupled with an Agilent GC-MS (Agilent 
Technologies, Wilmington, DE, USA) consisting of a 6890N series gas chromatograph, 
and a 5975 series mass selective (MS) detector. The HS vial was initially incubated at 40 
°C for 1 min, the septum was punctured using dual needles and nitrogen was delivered 
through the headspace of the vial to carry DMTS to the adsorptive material (Tenax® TA) 
where it was collected. The trapping and the incubation temperatures were set at 28 and 40 
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°C, respectively. The transfer heater temperature was set at 75 °C. After trapping for 10 
mins, the TDU tube was inserted into the TDU and was heated from 30 °C to 280 °C at a 
rate of 12 °C/s. The analyte was desorbed at 275 °C and transferred to a cooled injection 
system (CIS) PTV-type inlet, where it was trapped at 100 °C on a CIS liner. The CIS liner 
was then heated to 275 °C at a rate of 12 °C/s to transfer the analyte to the GC column 
before returning to its initial temperature. 
A DB5-MS bonded-phase column (30 m x 0.25 mm i.d., 0.25 µm film thickness; 
J&W Scientific, Folsom, CA, USA) was used with helium as the carrier gas at a flow rate 
of 1.0 mL/min and a column head pressure of 10.0 psi. The initial GC oven temperature 
was 30 °C and was held for 1 min, then elevated at a rate of 120 °C/min up to 250 °C, 
where it was held constant for 2 min, before returning to its initial temperature. The 
retention times for both DMTS and IS were about 3.5 min. The GC was interfaced with an 
MS detector with electron ionization (EI). DMTS and IS were identified and quantified 
using selective-ion-monitoring (SIM) mode at m/z of 126 ([CH3-S-S-S-CH3]+, 
quantification) and 111 ([CH3-S-S-S]+, identification), and 132 ([CD3-S-S-S-CD3]+, 
quantification) and 114 ([CD3-S-S-S]+, identification), respectively. 
 
2.3.5. Calibration, quantification, and limit of detection 
The proposed method was validated following the Food and Drug Administration 
(FDA) bioanalytical method validation guidelines [105-107]. Stock solutions of both 
DMTS (200 mM) and IS (100 mM) were prepared in methanol, which were further diluted 
with DI water to prepare the calibration standards (0.2, 0.5, 1, 2, 5, 10, 20, and 50 µM) and 
quality-control (QC) standards (0.75, 7.5, and 35 µM) for DMTS in denatured rabbit blood. 
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Each calibration standard was prepared in triplicate, where the concentration of IS was 2 
µM. To construct a calibration curve, the average peak area signal ratios of DMTS to IS 
were plotted as a function of calibrator concentrations. Peak areas of both DMTS and IS 
were calculated by manual integration from baseline to baseline in Agilent ChemStation 
software (Santa Clara, CA, USA). To evaluate the calibration behavior of DMTS, a total 
of six preliminary calibration curves were constructed. Both linear (y = mx + c) and log-
log (log y = m log x + log a) regressions were used, with goodness-of-fit (GOF) quantified 
by percent residual accuracy (PRA) [108]. PRA was used, in conjunction with the 
coefficient of determination (R2), to more effectively quantify the GOF. R2 is 
accurately quantify GOF throughout the calibration range. The disadvantages of R2 are 
exacerbated when using a geometric series of concentrations for calibration standards and 
when calibration curves span 2 3 orders of magnitude, as in this study. Therefore, for a 
more accurate representation of the goodness-of-fit, PRA was reported in the manuscript, 
along with R2. 
produce a PRA of 90 100%. Preliminary studies and the validation experiment confirmed 
that a log-log curve fit best described the calibration behavior of DMTS, as also reported 
by Manandhar et al. [45].  
The upper and lower limits of quantification (ULOQ and LLOQ) were investigated 
using two inclusion criteria: (1) calibrator precision of <10% relative standard deviation 
(RSD), and (2) calibrator accuracy of ±15% of the nominal concentration compared to the 
concentration back-calculated from the calibration curve. In parallel with the calibration 
standards, three QCs (0.75, 7.5 and 35 µM as low, medium, and high, respectively) were 
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also prepared in the same way (not included in the calibration curve) and were analyzed in 
quintuplicate each day for 3 days in order to calculate the intraassay (within same day) and 
interassay (over 3 days, within 5 calendar days) accuracy and precision. The LOD, which 
was defined as the lowest DMTS concentration to reproducibly produce a signal-to-noise 
ratio (S/N) of 3, was calculated by analyzing blood samples spiked with DMTS 
concentrations below the LLOQ. Noise was calculated as peak-to-peak noise in blank 
solutions over the retention time of DMTS.  
 
2.3.6. Selectivity and stability 
Selectivity of the method was evaluated by confirming the absence of significant 
signals above the baseline in the blank over the retention time of DMTS, as determined by 
comparing blank rabbit blood and DMTS-spiked rabbit blood samples by the procedure 
Resolution of the DMTS peak was also calculated as a measure of selectivity by standard 
methods [109]. 
Short- and long-term storage stability of DMTS was evaluated in triplicate using 
denatured rabbit blood spiked with HQC and LQC concentrations at different storage 
conditions over multiple time periods. For short-term stability, both QCs were evaluated 
in the autosampler and under multiple freeze thaw (FT) cycles. The autosampler stability 
was evaluated by placing triplicates of low (0.75 µM) and high (35 µM) QCs on the 
autosampler of the GC at ambient temperature and analyzing them at approximately 0, 2, 
5, 10, and 24 h following preparation to ensure the integrity of DMTS during the course of 
analysis. Because of the evaporative loss of DMTS in blood, IS was also incorporated to 
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track the change of analyte signal with respect to time, but it was not considered when 
evaluating the autosampler stability, as it would correct for the loss of DMTS in blood 
during the analysis. For FT analysis, four sets of LQCs and HQCs were prepared in 
triplicates without IS. Three sets of QCs were stored in a -80 ºC freezer, while one set was 
analyzed on the same day after adding IS. After 24 h, all QC samples were thawed at room 
temperature (RT) by running tap water (about 25 ºC) over the base of the sample vials. To 
one set of thawed QCs, IS was added, the samples were centrifuged at 252 × g for 10 s and 
then analyzed. The remaining two sets of QCs were placed back in the -80 ºC freezer for 
24 h. This freeze-thaw cycle was repeated two more times to evaluate three FT cycles.  
Bench-top stability and long-term stability studies for DMTS at -20 and 4 °C have 
been reported by Manandhar et al. [45] and were not evaluated in this study. Manandhar et 
al. [45] recommended to immediately add acid to a blood sample, add IS, snap freeze, and 
keep samples at -80 ºC in order to store blood samples for DMTS analysis, but only 
performed a 5-day stability study to confirm this recommended procedure. Therefore, we 
extended this experiment to 90 days to evaluate how long DMTS can be stored under these 
conditions before inaccurate results are found. For this study, triplicates of LQC and HQC 
concentrations of DMTS in blood were prepared for storage and analyzed after 0, 1, 2, 5, 
10, 20, 30, 45, 60 and 90 days at -80 ºC. Both QCs were prepared in bulk (30 mL) in 50-
mL Falcon® conical tubes to minimize sample-to-sample variation in the original QC 
concentrations. IS was spiked before storage, and from these bulk QCs, 10 sets of LQCs 
and HQCs each were prepared in triplicate by simply transferring 1 mL of sample to a 4-
mL HPLC vial for each replicate. One set of IS-treated QCs were analyzed on the same 
day (i -frozen using a dry ice acetone bath before 
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storing them in a -80 ºC freezer. After 24 h, another set of QCs (in triplicate) were thawed 
and analyzed (Day 1). The same protocol was followed for the rest of the samples. For all 
the stability experiments, stability of DMTS was calculated as a percentage of the initial 
within ±10% of the initial signal. 
 
2.3.7. Matrix effect 
Matrix effects for the analysis of DMTS in blood were evaluated by comparing an 
aqueous calibration curve with a calibration curve in blood. The assessment of matrix 
effects reveals the direct or indirect alteration of response due to the presence of interfering 
substances in the blood sample. The slopes (m) of the log-log plots for the calibration 
curves in blood and aqueous solution were used to evaluate and quantify (i.e., mblood/maq) 
the matrix effect. The value of (mblood/maq) equal to 1 indicates no matrix effect, whereas 
less than 1 and greater than 1 represent suppression and enhancement effects, respectively. 
The effectiveness of IS to compensate the matrix effect was also evaluated by comparing 
the ratio of mblood/maq of non-corrected curves with the IS-corrected curves. 
 
2.4. Results and discussion 
2.4.1. GC-MS analysis of DMTS 
The analytical method presented here features simple and quick sample preparation 
for the analysis of DMTS from whole blood. The sample preparation involves only 3 steps: 
1) treatment of whole blood with acid (0.4% H2SO4), 2) addition of IS, and 3) mixing. An 
aliquot of the resulting mixture is transferred to a HS vial and analyzed via DHS-GC-MS. 
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During DHS, the TDU tube (filled with Tenax® TA sorbent) dynamically adsorbs 
chemicals within the headspace vapor, including DMTS. This process allows exhaustive 
extraction of the DMTS from the blood. The DMTS is then thermally desorbed into the 
GC-MS by heating the TDU tube. The selected ion chromatograms of DMTS-spiked blood 
(0.5 µM, at m/z = 111 and 126), IS-spiked blood (2 µM, at m/z = 114 and 132) and non-
spiked blood (m/z = 126 and 132) are plotted in Figure 2.1.  
 

















DMTS-spiked (0.5 µM) blood 
(m/z = 126)
DMTS-spiked (0.5 µM) blood 
(m/z = 111)
Non-spiked blood (m/z = 126)





Figure 2.1. SIM mode GC-MS chromatograms of A) DMTS-spiked blood (0.5 µM) and 
non-spiked blood at m/z of 126 (quantification ion, upper trace) and m/z of 111 
(qualification ion, lower trace), and B) IS-spiked blood (2 µM) and non-spiked blood at 
m/z of 132 (quantification ion, upper trace) and at m/z of 114 (qualification ion, lower 
trace). 
 
As shown in Figure 2.1, the method produced good selectivity, with DMTS and IS 
eluting at approximately 3.50 min and the blank containing no coeluting peaks at this time. 
The closest consistent peaks of DMTS-spiked blood eluted at about 3.40 (m/z = 126) and 
3.55 (m/z = 111) min, producing resolutions (Rs) of 2.38 and 1.22, respectively. The peak 
shapes for both DMTS and IS were sharp and symmetrical with peak asymmetry factors 
of <1.3 and <1.2, respectively.  




















IS-spiked (2 µM) blood (m/z = 132)
IS-spiked (2 µM) blood (m/z = 114)
Non-spiked blood (m/z = 132)
Non-spiked blood (m/z = 1 )
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Table 2.1 shows the analytical description of each previously published method for 
DMTS analysis from biological matrices as compared to the current method.  
 
Table 2.1: Comparison of some important features of published and the current method 





















Brain 588 30a 1.49 4.51b 38.0b 
HPLC-UV Blood 495 25a 11.6 35.2c 396c 
Manandhar 
et al. [45] 
SBSE-GC-
MS 












aTotal estimated sample preparation time 
bReported as 645  5435 ngDMTS/gbrain 
cReported as 4.45  50 µg/mL 
dLarge volume technique 
eSmall volume technique 
 
The main advantages of the current method are: 1) rapid and simple sample 
preparation, 2) sensitivity, 3) small required sample volume, and 4) minimal consumable 
use. First, the overall sample preparation time is only 10 min, with chromatographic 
analysis lasting approximately 12 min. Therefore, using the current method, roughly 72 
parallel samples could be processed and analyzed in a 24-h period. Quick blood sample 
preparation is vital for DMTS to minimize its unwanted loss, and the reported sample 
preparation time (i.e., 10 min) is the shortest time necessary for any published method. 
Second, the current method is extremely sensitive, allowing detection and quantification 
as low as 0.04 and 0.2 µM for the large and small volume approaches, respectively. This 
is the lowest LLOQ for the current methods by at least 2.5 times. Third, the required 
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volume technique), which is the smallest blood volume required for any of the current 
DMTS analysis methods (Table 2.1). Fourth, the current approach uses one TD tube 
(Tenax® TA) for the extraction of DMTS for the entirety study, which makes the extraction 
process more consistent and less demanding than that of the other methods in Table 2.1. 
The need for multiple stir bars and SPME fibers makes the SBSE and SPME methods more 
costly since the Tenax® tube and a single stir bar or SPME fiber are approximately the 
same cost. Moreover, compared with the stir bars and SPME fibers, the Tenax® does not 
directly contact the biological samples, allowing greater longevity. Therefore, the Tenax® 
tube can be reused many more times than the stir bars or SPME fibers before it degrades 
(e.g., a single Tenax® sorbent tube was used for every sample in the current study with no 
observed loss in performance). Besides these main advantages, the DHS technique requires 
no organic solvent, whereas the HPLC technique requires extraction with acetonitrile, and 
mobile phase constitutes of water and acetonitrile in the ratio of 35 : 65 v/v. 
 
2.4.2. Dynamic range, limit of detection, and sensitivity 
Initially, the linearity of the method was evaluated in the range of 0.2 - 200 µM in 
blood. Multiple calibration curves were constructed to analyze the calibration behavior of 
DMTS by plotting the concentration of DMTS versus the signal ratio (i.e., peak area of 
DMTS at m/z 126 divided by the corresponding peak area of IS at m/z 132) as linear and 
log-log regressions over multiple calibration ranges. We confirmed that the calibration 
behavior of DMTS was best described by a log-log relationship. Manandhar et al. [45] also 
showed similar behavior of DMTS, which was explained by increased formation of the 126 
35 
 
(m/z) fragment at higher concentrations of DMTS in the ionization chamber (i.e., 
enhancement of MS ionization process at higher DMTS concentrations), independent of 
the sample preparation process. The largest two calibration standards (100 and 200 µM) 
did not meet the accuracy and/or precision inclusion criteria, resulting in a quantification 
range of 0.2 µM (LLOQ) to 50 µM (ULOQ). This linear range spanned over two orders of 
magnitude, as is desired for analysis of biological samples [77, 110]. Moreover, the LLOQ 
(0.2 µM) was much lower than the LLOQs for the HS-SPME-GC-MS and HPLC-UV 
methods reported by Kiss et al. [104], and is 2.5 times lower than the SBSE-GC-MS 
method of Manandhar et al. [45] (see Table 2.1). 
Table 2.2 shows the calibration curve equations of three separate calibration curves 
prepared over a 3-day period with their corresponding R2 and PRA values. All three 
calibration curves were found to be highly stable in terms of slope, R2, PRA, accuracy, and 
precision. 
 
Table 2.2: Curve equations and related values. 
Day Equation m PRA R2 Accuracy (%) 
Precision 
(%RSD) 
Day-1 log y = 1.07 log x  0.76 1.07 90.0 0.9962 100±14.9 <9.3 
Day-2 log y = 1.13 log x  0.80 1.13 95.8 0.9989 100±11.8 <7.5 
Day-3 log y = 1.15 log x  0.83 1.15 90.0 0.9965 100±14.6 <9.3 
 
The LOD of DMTS for the current method was 0.04 µM (large volume technique), 
which is 1.5 times lower than that of the Manandhar et al. [45] method, and significantly 
better than the reported LODs of Kiss et al. (1.49 and 11.56 µM [104]). The LOD was 
selected based on the concentration producing a signal-to-noise ratio of 3:1. This high 
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sensitivity is very important to accurately quantify DMTS in blood samples at typical doses 
of DMTS [111]. 
 
2.4.3. Accuracy and Precision 
Although DMTS is very unstable and volatile in nature, the accuracy and precision, 
reported in Table 2.3, were excellent relative to other methods of DMTS analysis from 
blood. To perform the study, three QC standards (0.75, 7.5 and 35 µM) were analyzed in 
quintuplicate on three different days within six calendar days. FDA method validation 
guidelines were followed to evaluate the results [106, 112, 113] and the obtained intraassay 
accuracy (100 ± 8-15%) and precision (<10% RSD), and inter-assay accuracy (100 ± 9%) 
and precision (<9% RSD), were remarkable. 
 




 Intra-assay  Inter-assay 
 Accuracy (%)a  Precision (%RSD)a  Accuracy 
(%)b 
Precision 
(%RSD)b  Day 1 Day 2 Day 3  Day 1 Day 2 Day 3  
0.75  100±7.8 100±11.1 100±2.9  5.9 3.7 6.1  100±5.4 8.3 
7.5  100±1.6 100±14.1 100±13.5  3.8 2.9 2.7  100±8.7 8.6 
35  100±5.4 100±5.8 100±1.7  6.5 6.0 9.0  100±3.2 7.9 
aQC method validation (n = 5). 
bAverage of three different days of QC method validation (n = 15). 
 
2.4.4. Matrix effect and storage stability 
To evaluate the matrix effect, two types of calibration curves were constructed 
(non-IS corrected and IS-corrected curves) in both blood and in aqueous samples. The ratio 
of slopes (mblood/maq) was 0.90 (Table 2.4), indicating only a minor matrix effect for the 
analysis of DMTS in blood. Moreover, the IS-corrected slope ratio (mblood/maq) was 0.98, 
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revealing the importance of IS for correcting for any loss of analyte signal during DMTS 
analysis process. 
 
Table 2.4: Slopes obtained from non-IS corrected and IS-corrected calibration curves of 
DMTS. 
Calibration curve mblood maq mblood/maq Remark 
Non-IS corrected 0.98 1.09 0.90 Minor matrix effect 
IS-corrected 1.13 1.15 0.98 Corrected matrix effect 
 
The short-term stability of DMTS in blood was evaluated in the autosampler over 
24 h at ambient temperature and under multiple FT cycles. Results obtained from the 
autosampler stability showed that both QC concentrations of DMTS were unstable during 
the investigated time period. Without IS correction, the loss of DMTS signals from both 
QCs were approximately 50% of time zero after 10 h, which was expected, and  likely 
caused mainly by the rapid enzymatic degradation of DMTS in blood. After 24 h, signal 
loss was exacerbated, with only about 16% of DMTS signal from both QCs recovered. 
Although the raw DMTS signals were unstable, the IS-corrected signals showed the 
ire 24 h. Therefore, we recommended leaving 
prepared samples on the autosampler for periods of time not longer than 10 h, but if 
necessary, the IS correction can provide accurate quantification of DMTS over 24 h of 
storage on the autosampler. The FT stability test showed that DMTS is lost with each FT 
cycle, with almost 40% of DMTS signal loss after the first FT cycle.  Similar outcomes 
were also reported by Manandhar et al. [45], reasoning that this is due to complex 
enzymatic activity. So, thawing and re-freezing blood samples should be avoided, but if it 
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is necessary, then IS should be added during sample preparation to correct the loss of 
DMTS signal during thawing process.  
For long-term stability investigations, low and high QCs of DMTS spiked blood 
ed periodically for 90 days. The 
purpose of this study was to evaluate the effectiveness of the storage protocol 
recommended by Manandhar et al. [45], where acid is used to denature blood proteins, IS 
Our results showed that the DMTS signal loss (without IS correction) from both QCs was 
about 40% over 60 days, which was in agreement with the findings from our FT stability. 
Over the next 30-day period the non-IS-corrected signal loss was drastic (i.e., almost 90% 
loss com -corrected DMTS signals were consistent 
(100±10% of Day 0), again showing to value of the IS to provide accurate DMTS 
concentrations during storage.  
Considering the storage stability results in aggregate, similar to Manandhar et al. 
[45], we recommend immediate acid denaturation of biological samples, addition of 
DMTS-d6 
stable for 60 days with IS correction. Multiple thawing and refreezing of samples should 
be avoided, and prepared samples should b  
 
2.4.5. Pharmacokinetic study of DMTS-treated animals  
The validated DHS-GC-MS method was applied to the analysis of blood samples 
from a pharmacokinetic study of DMTS in treated rats. Figure 2.2 shows the 
chromatograms of treated and untreated rat blood. DMTS was detected at 3.65 min, 
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whereas no peak was found at the retention time of DMTS in the blood of untreated rats. 
This slight shift in retention time is due to the installation of a new column before the 
analysis of pharmacokinetic study samples. 
 
Figure 2.2. Representative GC MS chromatograms of the blood of DMTS-treated and 
untreated rats (m/z 126). 
 
Figure 2.3 shows the plasma concentration-time curve of DMTS pharmacokinetics 
in rats. In terms of the DHS-GC-MS analysis of DMTS, the relatively low DMTS 
concentrations found in the blood of IM-treated rats mean that both the HPLC-UV and 
SPME-GC-MS techniques (Table 2.1) would not allow quantification of DMTS-spiked 






















Blood of DMTS-treated rats
Blood of untreated rats
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possibility that the SBSE-GC-MS method may allow quantification of DMTS, the current 
method would need to be modified to allow analysis of lower volumes of blood.  
 
Figure 2.3. Blood concentration-time behavior of DMTS following IM administration of 
DMTS solution to rats. Each value is expressed as mean ± SEM (n = 5). 
 
The pharmacokinetic results, although preliminary, reveal that DMTS is absorbed 
and distributed very quickly with a Cmax (the maximum concentration of a drug achieved 
in the plasma following dose administration) and tmax (the time at which Cmax is attained) 
of 0.89±0.09 µM and 10 min, respectively. Moreover, the blood DMTS concentration at 
the earliest time point (2 min) (0.87±0.06 µM) was not significantly different from 























administration is promising, in that it should allow fast treatment of cyanide throughout the 
body by untrained personnel. Additionally, DMTS showed a long elimination half-life (t1/2 
= 630 min or 10.5 h), with an estimated elimination rate constant (kE) of 0.0011 min-1. This 
behavior allows early and continuous protection for long periods of time after DMTS 
treatment. Overall, this preliminary pharmacokinetic data showed impressive behavior of 
DMTS, most notably quick onset of action and slow elimination.  
 
2.5. Conclusions 
A simple, relatively affordable, and highly sensitive DHS-GC-MS method for the 
rapid analysis of DMTS in blood was developed. When considered in aggregate this 
validated method is superior to other published approaches in terms of its ability to detect 
and quantify low concentrations of DMTS (0.04 and 0.2 µM, respectively), its simple and 
rapid sample preparation scheme (<10 min), and the low required blood volume (50 µL). 
Relative to other methods of DMTS analysis from blood, the method presented here 
produced consistently good recovery, high sensitivity, excellent accuracy, outstanding 
precision, and minimal matrix effect. Moreover, the recommended storage procedure 
allows analysis of blood samples for DMTS up to 60 days following collection. Because 
-
the analysis of DMTS blood concentrations from drug development studies of DMTS. 
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Chapter 3. Analysis of the Soil Fumigant, Dimethyl Disulfide, in Swine Blood by 
Dynamic Headspace Gas Chromatography Mass Spectroscopy 
 
3.1. Abstract 
Plant parasites and soilborne pathogens directly reduce the overall yield of crops, 
vegetables, and fruits, negatively impacting the market demand for these products and their 
net profitability. While preplant soil fumigation helps maintain the consistent production 
quality of high-value cash crops, most soil fumigants are toxic to off-target species, 
including humans. Dimethyl disulfide (DMDS) has recently been introduced as a relatively 
low toxicity soil fumigant. Although DMDS exhibits low toxicity compared to other soil 
fumigants, it is volatile and exposure can cause eye, nasal, and upper respiratory tract 
irritation, skin irritation, nausea, dizziness, headache, and fatigue. While there is one 
analysis method available for DMDS from biological matrices, it has significant 
disadvantages. Hence, in this study, a dynamic headspace gas chromatography mass 
spectroscopy (DHS-GC-MS) method was developed for the analysis of DMDS in swine 
whole blood. This method is highly sensitive and requires only three steps: 1) acid 
denaturation, 2) addition of internal standard, and 3) DHS-GC-MS analysis. The method 
produced a wide linear range from 0.1  200 µM with an excellent limit of detection of 30 
nM. Intra- and interassay accuracy (100±14% and 100±11%, respectively) and precision 
(<5% and <6% relative standard deviation, respectively) were also excellent. The method 
worked well to quantify the DMDS level in the blood of dimethyl trisulfide (DMTS)-
treated swine (i.e., DMDS is a byproduct of DMTS treatment) with no interfering 
substances at or around the retention time of DMDS (i.e., 2.7 min). This simple, rapid, and 
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extremely sensitive method can be used for the quantification of DMDS levels in blood to 
verify exposure to DMDS or to monitor levels of DMDS following DMTS treatment (e.g., 
for cyanide poisoning). 
 
3.2. Introduction 
Preplant soil fumigation is the most direct and effective way to guarantee crop 
output and quality by controlling plant-parasitic nematodes, soilborne pathogens, and 
weeds [114, 115]. It is a popular process for high-value cash crops, including blueberries, 
cranberries, strawberries, vegetables (e.g., tomatoes), cucurbit crops (e.g., squash), nursery 
crops, fruit trees, forest nurseries and ornamental plants [116-118]. Its effectiveness, 
environmental impacts and human health risks are mostly dependent on the chemical used, 
the method of delivery, soil type and condition, and meteorological conditions [119]. While 
application of soil fumigants is popular, all soil fumigants are volatile, leading to an 
abundance of mobile toxic compounds in the air and creating human inhalation health 
hazards. These substances may also act as potential precursors for photochemical smog 
formed by the reaction of volatile organic chemicals (VOCs) with nitrogen oxides [119, 
120]. While measures can be adopted to minimize human exposure (e.g., posting warning 
signs, entry restriction, on-site supervision, use of respiratory protection, tarp and buffer 
zone consideration), it is difficult to decrease the risk of exposure to negligible levels [117, 
121]. Among the commercially available preplant soil fumigants, methyl bromide, metam 
sodium or potassium, dazomet, chloropicrin, 1,3-dichloropropene and dimethyl disulfide 
(DMDS) are commonly used [122]. 
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Methyl bromide was the preferred preplant soil fumigant in the USA since its 
registration in 1961 until it was internationally banned in 2015. It is a colorless and 
nonflammable gas with a half-life in soil of about 55 days at 25 °C. Although it is a highly 
effective fumigant, it is acutely toxic to humans, producing headache, dizziness, nausea, 
eye, nose and throat irritation, chest and abdominal pain, delayed pulmonary edema, 
shortness of breath, and nervous system disfunction if exposure is long term [123]. 
Additionally, it has been shown to have a role in depleting stratospheric ozone [116, 117]. 
Metam sodium, metam potassium, and dazomet are methyl isothiocyanate (MITC) 
generating fumigants, forming MITC as a breakdown product in soil, which kills 
nematodes, weeds, plant pathogens and insects. While MITC generators are considered 
more toxic than methyl bromide, they have short residence times in soil, dissipating at a 
rate of about 20% per day at 25 °C. MITC is a powerful lachrymator and has horseradish 
like odor. Short-term and prolonged exposure to MITC produces similar symptoms to 
methyl bromide [123, 124].  
Chloropicrin, which has been used for decades to control soilborne fungi and 
nematodes, was first approved in the USA as a soil fumigant in 1975 [120]. It can be used 
alone or in combination with 1,3-dichloropropene or DMDS to broaden its effectiveness to 
pest control [123]. Because of its high vapor pressure (3.2 kPa at 25 °C), it disperses 
through the soil mainly as a gas and is nonpersistent in the soil, requiring tarps or adequate 
irrigation after application. Low level exposure causes eye and upper respiratory tract 
inflammation, but severe exposure can cause damage in the respiratory tract system and 
life-threatening pulmonary edema [123, 125].  
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1,3-Dichloropropene has been used as a preplant soil fumigant to control nematodes 
since the early 1950s. Like chloropicrin, it also has a low boiling point (104 °C), is slightly 
soluble in water, has low persistence in the soil, and requires tarps or adequate irrigation 
after application. The toxic effects of 1,3-dichloropropene include severe eye and 
respiratory irritation, kidney damage, and carcinogenic effects [120, 126]. In 1990, 1,3-
dichloropropene was banned in California based on its kidney damaging behavior. It has 
also been banned as a pesticide in the European Union. Moreover, it was listed by the EPA 
[120, 123].  
Because of the disadvantages associated with current soil fumigants, the search for 
a more environment friendly, less toxic, economically feasible alternative is of great 
significance. DMDS is a recently approved soil fumigant that is used alone or in 
combination with chloropicrin to control soilborne pathogens, bacteria, fungi, and weeds. 
It was introduced in the US in 2010 and is now used worldwide. DMDS is a transparent, 
pale yellowish liquid with a half-life in air of about one hour [127, 128]. It evaporates 
readily from soil and does not persist or accumulate in the air or water. Because of its high 
vapor pressure, application of high-barrier tarps is necessary immediately after fumigation 
with DMDS and a buffer zone is also required to minimize unwanted exposure and to 
improve efficacy of the fumigant [117, 127]. DMDS has a strong garlic-like pungent odor 
that humans can detect at a very low concentrations (7-12 ppb) [129], therefore, humans 
can generally avoid high dose inhalation exposure to DMDS [130]. Three products 



















Paladin 55050-4 July 09, 
2010 
98.8 Blueberry, Caneberry, Cucumber, 
Eggplant, Forest nursery, Melon, 




55050-5 July 09, 
2010 
93.8 Blueberry, Cucumber, Eggplant, 
Forest nursery, Fruit tree, Irrigation 
system, Melon, Nursery crop, 
Ornamental plant, Pepper, Squash, 
Strawberry, Tomato, Vegetable crop 
Paladin  
Pic-21 
55050-7 June 14, 
2016 
78.1* Blueberry, Cucumber, Eggplant, 
Forest nursery, Melon, Ornamental 
plant (field), Ornamental plant, 
Pepper, Squash, Strawberry, Tomato 
*Also contains Chloropicrin (20.9%) 
 
Two of them, Paladin (98.8% DMDS) and Paladin EC (93.8% DMDS), were first 
registered in 2010. The third product, Paladin Pic-21, was approved for use in 2016, and is 
a mixture of 78.1% DMDS and 20.9% chloropicrin [117]. The addition of chloropicrin to 
DMDS fumigants broadens the pest control spectrum by significantly increasing the soil 
persistence of the combination fumigant [131, 132], but it also increases the overall 
toxicity. Although DMDS exhibits relatively low toxicity, it is a potential eye and skin 
irritant and can affect the central nervous system during acute exposure [127]. Exposure to 
large concentrations may cause nausea, headache, dizziness, and irritation of the upper 
respiratory tract. This leads to sneezing, coughing, sore throat, dyspnea, chest tightness, 
and a feeling of suffocation. Besides use as a soil fumigant, DMDS is also used as a food 
additive and as a sulfiding agent in the petrochemical industry [127, 133]. Moreover, it is 
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a breakdown product of dimethyl trisulfide (DMTS), a promising next generation cyanide 
antidote [17, 45, 134].     
Although DMDS has been reported to cause acute illness [127, 135], there is no 
sensitive method available to determine the low level of exposure of DMDS in biological 
samples. One analytical method is available featuring a headspace gas chromatography-
flame ionization detector (HS-GC-FID) screening technique [136], which has significant 
disadvantages. The main disadvantage of this method is that it is very insensitive, reporting 
the method can 
only quantify extremely high blood concentrations of DMDS (1.06  8.49 mM; reported 
as 0.1  0.8 mg/mL). The insensitivity of the method makes it suitable for only very high 
dose exposures to DMDS. 
Because of the interest in DMDS as a fumigant and for other purposes, especially 
to evaluate DMDS concentrations in drug development studies of DMTS as a possible 
cyanide countermeasure, there is a critical need for a more sensitive method of analysis for 
DMDS from biological matrices. The objective of this study was to develop and validate 
an effective dynamic headspace (DHS) gas chromatography-mass spectrometry (GC-MS) 
analysis technique for the detection of DMDS in swine whole blood. The usefulness of the 
method was tested by determining DMDS levels produced in swine treated with DMTS. 
 
3.3. Experimental 
Caution: Besides toxicity associated with DMDS, it and its deuterated internal 
standard (DMDS-d6), both compounds are flammable liquids (i.e., flashpoints below 23 
°C, Category 2  that are prone to ignite at normal working temperatures. Therefore, 
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DMDS was handled utilizing appropriate safeguards, including storage of DMDS 
solutions in a flammable material storage refrigerator and completing all sample 
preparation in a well-ventilated hood. 
 
3.3.1. Materials 
All reagents were high-performance liquid chromatographic (HPLC) grade unless 
otherwise noted. Methanol and sulfuric acid (certified ACS plus) were obtained from 
Fisher Scientific (Fair Lawn, NJ, USA).  Reverse-osmosis water was purified to a 
resistivity of -cm by passing through Lab Pro polishing unit from Labconco 
Corporation (Kansas City, KS, USA). DMDS and internal standard (IS), DMDS-d6, were 
purchased from Alfa Aesar (Heysham, Lancs, UK) and Toronto Research Chemicals 
(North York, ON, Canada), respectively, and stored in a flammable material storage 
refrigerator for future use. For each experiment, a freshly prepared working solution of 
DMDS (200 mM in methanol) was used to create calibrators and quality-control (QCs) 
samples. The stock solution of IS (5 mM) was prepared in methanol. This stock solution 
was further diluted to 500 µM in DI water for each analysis and kept in a refrigerator. A 
thermal desorption (TD) tube filled with Tenax® TA sorptive material was purchased from 
Gerstel Inc. (Linthicum, MD, USA) and conditioned at 315 °C for 8 h under ultra-high 
purity nitrogen gas (Grade 5.0 from A-OX Welding Supply Co., Sioux Falls, SD, USA) 
flow (68 psi) using a tube conditioner (TC 2) and Gerstel Aux-controller 163 (Linthicum, 
MD, USA). One TD tube was used for the entire study, including method development and 




3.3.2. Biological samples 
For method development and validation, swine whole blood (non-sterile with 
sodium EDTA) was purchased from Pel-Freez Biologicals (Rogers, AR, USA) and kept in 
The whole blood was thawed and 
spiked with DMDS, where appropriate, for method development and validation. 
Following validation, the effectiveness of the method was evaluated by analyzing 
the concentration of DMDS in the blood of DMTS-treated swine. This study was 
performed at University of Colorado Anschutz Medical Campus. All experiments were 
(IACUC) and complied with the regulations and guidelines of the Animal Welfare Act and 
the American Association for Accreditation of Laboratory Animal Care. Female Yorkshire 
swine (45-50 kg) were used for this study, and a detailed animal samples preparation 
process has been reported elsewhere [89]. In short, swine were anesthetized with ketamine 
and inhaled isoflurane. Following induction of anesthesia, animals were intubated, and 
sedation was maintained. Animals were instrumented for monitoring and recording of 
physiological parameters throughout the experiment. Following instrumentation, 
isoflurane was weaned until the animal was breathing spontaneously. Sedation was 
maintained with isoflurane throughout the experimental procedure to minimize pain and 
discomfort. After a 10-min acclimation period, animals were randomized into one of two 
treatment groups: IM DMTS or IM saline control. Potassium cyanide was then diluted in 
saline and delivered into the right jugular vein until 5 min after apnea occurred. At 5 min 
following apnea, animals were treated with either DMTS or saline control and the cyanide 
infusion was terminated. The DMTS treatment arm received 10 mg/kg DMTS injected into 
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the left gluteal muscle. Control animals received an equivalent volume of saline injected 
into the left gluteal muscle. Prior to cyanide exposure and administration of DMTS, 
baseline blood samples were collected. Following DMTS administration, blood samples 
were collected at 0.5, 1, 2, 5, 10, 20, 30, 40, 50, 60, 70, 80 and 90 min for evaluation of 
DMDS formation over time. Animals were observed and blood was drawn up to 90 min 
post-treatment or until death occurred, defined as a mean arterial pressure (MAP) of less 
than 30 mmHg for 10 min. 
For each blood sample obtained from the animal study, 500 µL of blood was 
withdrawn and transferred to a 2-mL centrifuge tube along with sulfuric acid (1 mL of 
0.4% w/v in DI water) with mixing. IS (25 µL of 42 µM) was immediately added and 
mixed well. All the prepared samples were then flash frozen and shipped (overnight) on 
dry ice to South Dakota State University (Brookings, SD, USA) for analysis. Upon receipt, 
the blood samples were stored in a 80 °C freezer until analysis. 
 
3.3.3. Sample preparation for DHS-GC-MS analysis 
For method development and validation, standards were prepared by transferring 
475 µL of swine whole blood and 1 mL of aqueous sulfuric acid (0.4%) to a 4 mL glass 
screw-top vial. The mixture was then vortexed briefly (10 s) at 3000 rpm (252 × g) to 
ensure protein precipitation and enzyme denaturation. Note that DMDS is unstable in non-
denatured blood, therefore, sample preparation in acid denatured blood is a crucial step 
to minimize its rapid enzymatic degradation in blood. Then, a 1:1 mixture of DMDS:IS 
solution (50 µL) was spiked into the acidified blood. The IS final concentration was 2 µM. 
The standard was vortexed for 10 s at 3000 rpm (252 × g), and an aliquot (100 µL) of the 
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mixture was transferred to a 20-mL headspace (HS) vial with a polytetrafluoroethylene 
(PTFE) lined septum for analysis.  
As indicated above, for samples obtained from DMTS-treated animals, 
acidification was performed immediately after withdrawing the blood. Subsequently, IS (2 
µM final concentration) was then quickly added, the samples were mixed and then flash 
frozen, and stored at -80 °C until immediately prior to analysis. At the time of analysis, the 
blood samples were thawed by running ambient tap water over the sample until the sample 
was completely thawed. An aliquot (100 µL) of the acidified blood was transferred to a 20 
mL headspace (HS) vial with a polytetrafluoroethylene (PTFE) lined septum for analysis.  
 
3.3.4. DHS-GC-MS analysis 
DHS extraction was performed using a Gerstel automated DHS station via a 
MultiPurpose Sampler (MPS) (Linthicum, MD, USA). Sample analysis was accomplished 
via an Agilent GC-MS system (Wilmington, DE, USA) consisting of a gas chromatograph 
(6890N series) and mass selective detector (5975 series). Initially, the HS vial was 
incubated in the DHS station for 1 min at 40 °C, then the PTFE septum was punctured 
automatically by a dual needle assembly. Ultra-high purity nitrogen gas (Grade 5.0) was 
delivered through the needle at a rate of 30 mL/min for 10 min to purge the headspace of 
the sample vial to trap the DMDS on the Tenax® TA adsorptive material. The trapping, 
incubation and transfer heater temperatures were set at 28, 40 and 75 °C, respectively. After 
trapping, the TD tube was transferred to the thermal desorption unit (TDU) and heated 
from 30 °C to 280 °C at a rate of 720 °C/min to transfer DMDS to a cooled injection system 
(CIS) programmable temperature vaporization (PVT) type inlet, where a CIS liner trapped 
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the DMDS at -100 °C. Splitless desorption mode was used, and the TDU transfer heater 
temperature was maintained at 275 °C. To transfer the DMDS from the CIS to the GC 
column, the CIS temperature was increased to 275 °C at a rate of 12 °C/s before returning 
to its initial temperature.  
For chromatographic separation, a DB5-MS bonded-phase column (30 m length × 
0.25 mm inner diameter, 0.25 µm film thickness) purchased from J & W Scientific 
(Folsom, CA, USA) was used with helium (Ultra high purity, grade 5.0 from A-OX 
Welding Supply Co., Sioux Falls, SD, USA) as the carrier gas. The mobile phase flow rate 
was 1.0 mL/min and the column head pressure was 10.0 psi. The initial GC oven 
temperature was set at 30 °C for 1 min, then increased at 120 °C/min to 250 °C and held 
constant for 2 min, before returning to the initial temperature. An MS detector using 
electron ionization (EI) with an electron energy of 70 eV was used in selective ion 
monitoring (SIM) mode to monitor the quantification and identification ions of DMDS 
(m/z of 94 [CH3-S-S-CH3]+ and 79 [CH3-S-S]+, respectively) and IS (m/z of 100 [CD3-S-
S-CD3]+ and 82 [CD3-S-S]+, respectively). The retention times for both DMDS and IS were 
about 2.7 min. 
 
3.3.5. Calibration, quantification, and limit of detection 
The method validation was performed by generally following the Food and Drug 
Administration (FDA) bioanalytical method validation guidelines [106, 107, 137]. The 
calibration behavior of DMDS was evaluated by constructing six calibration curves over 
the preliminary dynamic range (i.e., 0.1  200 µM). Weighted and unweighted linear (y = 
mx + c) and unweighted log-log (log y = m log x + log c) regression models were evaluated 
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to determine the best fit model for analysis of DMDS. To quantify the goodness-of-fit 
(GoF) of the calibration models, percent residual accuracy (PRA, [108]) was used. For log-
based calibration, the PRA was based on the linear values of the nominal and calculated 
concentrations by taking the anti-log of the logarithmic calculated and nominal 
concentrations for comparison. Because it is commonly used for evaluating GoF,  the 
coefficient of determination (R2) was also calculated, but its value is predominantly based 
on the GoF of the highest concentration 2 or 3 calibrators and does not typically accurately 
quantify GoF throughout the calibration range [108]. Furthermore, the disadvantages of R2 
are exacerbated when using a geometric series of concentrations for calibration standards 
and when calibration curves span 2 3 orders of magnitude, as in this study. In order to set 
the calibration range, the lower and upper limit of quantification (LLOQ and ULOQ, 
respectively) were required to satisfy the inclusion criteria of <10% relative standard 
deviation (RSD, as a measure of precision) and ±15% percent deviation back-calculated 
from the nominal concentration (as a measure of accuracy). The limit of detection (LOD) 
was calculated by analyzing multiple concentrations of DMDS below the LLOQ and 
determining the lowest DMDS concentration which reproducibly produced a signal-to-
noise (S/N) ratio of at least 3. 
 
3.3.6. Accuracy and precision 
For evaluation of intra- and inter-day method performance, the stock solution of 
DMDS (200 mM in methanol) was diluted in DI water to prepare calibration standards 
(0.1, 0.2, 0.5, 1, 2, 5, 10, 20, 50, 100 and 200 µM) and quality control (QC) standards (0.35, 
7.5 and 75 µM) in acid-denatured swine blood. All QC standards (0.35, 7.5 and 75 µM) 
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were prepared in quintuplicate and run in parallel with the calibration standards each day 
for three days. IS (2 µM) was spiked into blanks, calibrators, and QCs to correct for 
multiple sample-to-sample errors. Following analysis, calibration curves were constructed 
by plotting the log of the average peak-area signal ratios of DMDS to IS as a function of 
the log blood DMDS concentrations. T
and interassay (calculated by comparing data obtained over three separate days, within five 
calendar days) accuracy and precision were quantified, with accuracy calculated as the 
percent difference of the calculated and nominal DMDS concentration of the QCs and 
precision quantified as the %RSD of the QCs. Precision and accuracy requirements were 
10% RSD, respectively. Agilent ChemStation software (Santa Clara, 
CA, USA) was used to calculate the peak areas of both DMDS and IS.  
 
3.3.7. Recovery and matrix effect 
The recovery of DMDS was determined by comparing the signals of triplicates of 
low (0.35 µM), medium (7.5 µM) and high (75 µM) aqueous QCs with the equivalent 
concentration QCs in swine blood. Recovery (which was calculated as a percentage) was 
determined by dividing the peak area of DMDS signal in blood by the peak area of the 
equivalent concentration aqueous QC. The recovery obtained this way may not reflect true 
recovery because of the possible interaction (i.e., matrix effect) between DMDS and the 
blood matrix. Therefore, to evaluate the matrix effect, two calibration curves (abundance 
vs. concentration) of DMDS were prepared  one was prepared in DI water, where blood 
was replaced by DI water during sample preparation, and another one was constructed in 
swine blood. The ratio of the slopes of the calibration curves (i.e., mblood/maq), where mblood 
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is the slope of the calibration curve from calibrators in swine blood and maq is the slope 
based on aqueous calibrators, was used to quantify the matrix effect, which was obtained 
from the log-log plots for blood and aqueous calibration curves. A slope ratio of <1 and >1 
represent suppression and enhancement effects, respectively, whereas a ratio of 1 indicates 
negligible matrix effect. To evaluate the effectiveness of the IS for correcting for matrix 
effects, two other calibration curves were also constructed by plotting the signal ratio of 
DMDS to IS versus the concentration of DMDS for both aqueous and blood calibrators 
and comparing the slopes (i.e., mblood(IS-corrected)/maq(IS-corrected)). For an IS to be considered 
effective, the difference in slopes should be negligible. 
 
3.3.8. Selectivity and stability 
The selectivity of this method was determined by confirming the consistent absence 
of interfering peak(s) at or near the retention time of DMDS in the blank swine blood 
sample. As a measure of selectivity, the resolution (Rs) was calculated between the DMDS 
peak and the peak which consistently eluted nearest the DMDS retention time (2.7 min). 
The short- and long-term stabilities of DMDS were assessed by analyzing 
triplicates of low and high QCs of DMDS-spiked blood samples at different storage 
conditions over multiple predetermined time periods. For all stability experiments, the 
t
considered stable if the peak response from a stability standard was within ±10% of the 
initial (time 0) response. Bench-top, autosampler and freeze-thaw stabilities were evaluated 
as a part of the short-term stability study. For bench-top stability, DMDS-spiked non-
denatured blood for both QCs were kept at room temperature for 0, 2, 5, 10 and 24 h prior 
57 
 
to analysis. Samples were then analyzed in triplicate after spiking acid (1 mL 0.4% H2SO4) 
and IS (25 µL 42 µM) to each QC. To evaluate autosampler stability, triplicates of low and 
high QCs were placed at on the GC autosampler at ambient temperature and the samples 
were then analyzed at approximately 0, 2, 5, 10, and 24 h to confirm the integrity of DMDS 
during the period of analysis. Because DMDS showed rapid degradation in blood, the 
ability of the IS to correct for the loss of DMDS during analysis was evaluated by 
comparing the IS-  
Freeze-thaw stability samples were prepared by spiking DMTS in swine blood and 
treating in three different ways: (a) in non-denatured blood followed by unassisted freezing 
in the storage condition, (b) in non-denatured blood followed by flash-freezing, and (c) in 
acid-denatured blood followed by flash-freezing in liquid nitrogen. A summary of the 
freeze-thaw stability sample preparation is presented in Table 3.2.  
 
Table 3.2: Freeze-thaw sample preparation. 
Sample 
Before storage  Before analysis 
Acid added IS added Flash-freezing  Acid added IS added 
 No No No  Yes Yes 
 No No Yes  Yes Yes 
 Yes No Yes  No Yes 
 
Five sets of low and high QCs were prepared in triplicates for all three conditions 
without IS. One set of samples was 
 for blood 
denaturation process before flash-freezing). To evaluate loss of DMDS with and without 
flash freezing, stability standar -80 °C and the standard 
-frozen before storing the samples in a freezer. After 24 hr, all 
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stored samples were thawed at room temperature by applying ambient tap water over the 
base of the vials containing sample mixture. Immediately after fully thawing the standards, 
 
with the remaining three sets of QCs returned to the -80 ºC freezer for storage. Thawed 
samples for analysis were vortexed at 252 × g for 10 s and analyzed. The entire process 
was repeated three more times to evaluate four freeze-thaw cycles.  
Long-term DMDS stability was evaluated by analyzing triplicates of low and high 
QCs at 4, -30 and -80 °C to check how long DMDS samples can be stored under different 
stability conditions. For this, both QCs were prepared in bulk for each temperature 
condition to minimize unwanted sample-to-sample variation. The QCs were analyzed after 
0, 1, 2, 5, 30, 45, 70 and 90 days. From the bulk preparations, triplicates of eight sets of 
low and high QCs were prepared by transferring one sample volume of an acid-denatured 
and DMDS-spiked blood sample mixture (i.e., 1.525 mL) to a 4-mL glass screw-top vial 
standards were prepared and the other seven sets of samples for each temperature condition 
were stored at 4, -30, or -80 °C. Another set of three of long-term stability samples were 
prepared at the same time by following the same protocol, but flash-freezing was 
performed prior to storing at -80 °C using liquid nitrogen. The flash frozen storage stability 
stan -
- h 
liquid nitrogen) were removed from all three storage conditions, thawed by applying 
ambient tap water over the base of the vials, and then analyzed. The same procedure was 
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followed to analyze the rest of the samples at designated storage times. For freeze-thaw 
and long-term stability experiments, the stability of DMDS was calculated as a percentage 
was ±10% of the initial signal. 
 
3.4. Results and discussion 
3.4.1. GC-MS analysis of DMDS 
The method proposed here is a sensitive analytical method for measurement of 
DMDS from a blood sample. The method features simple and rapid sample preparation 
from whole blood, requiring only three steps: 1) addition of sulfuric acid and IS, 2) mixing, 
and 3) analysis via DHS-GC-MS. This rapid sample preparation (<10 min) is vital for 
DMDS, as it minimizes the rapid degradation and unwanted evaporative loss of DMDS. A 
small volume of blood (100 µL) is required, and the method is environmentally friendly, 
requiring no organic solvents. With a sample preparation time of 10 min, and a total 
chromatographic analysis time (i.e., considering the DHS sample trapping time and CIS 
cooldown time) of about 12 min, the method can analyze 72 samples in parallel over a 24-
h period. Moreover, the method requires minimal consumables and is more consistent than 
other related methods. The consistency of the method was aided by using one TD tube for 
the entirety of the study based on the robustness of the Tenax® sorbent and the fact that it 
does not directly contact the blood sample. Therefore, the DHS vials and caps and the 
pipette tips were the only consumables necessary for the method. 
Figure 3.1 shows overlaid chromatograms of (A) DMDS-spiked blood (0.5 µM) 
and non-spiked blood (at m/z = 94 and 79), and (B) IS-spiked blood (2 µM) and non-spiked 
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blood (at m/z = 100 and 82). The peaks for both DMDS and the DMDS-d6 eluted at about 
2.7 min, with no interfering peaks observed at or near the retention time of DMDS. The 
resolution (Rs) of DMDS and the closest consistently eluting peak (2.95 min) for the 
quantification ion (m/z of 94) was 4.76, indicating excellent selectivity. Moreover, both 
DMDS and its IS showed sharp and generally symmetrical peaks, with peak asymmetry 
factors (As) of <1.4 and <1.3, respectively, indicating only slight tailing. Tailing factors 
(Tf) of 1.32 for DMDS and 1.23 for the IS, also indicate slight tailing and were well within 
the acceptable range (Tf <2.0). The number of theoretical plates (N) was about 2×105 
(calculated based on DMDS), indicating excellent column efficiency.  
 
 
















DMDS-spiked (0.5 µM) blood (m/z = 94)
DMDS-spiked (0.5 µM) blood (m/z = 79)
Non-spiked blood (m/z = 94)





Figure 3.1. GC-MS chromatograms (in SIM mode) of A) DMDS-spiked (0.5 µM) and 
non-spiked blood at m/z of 94 (quantification ion, upper trace) and m/z of 79 (qualification 
ion, lower trace), and B) IS-spiked (2 µM) and non-spiked blood at m/z of 100 
(quantification ion, upper trace) and at m/z of 82 (qualification ion, lower trace). 
 
3.4.2. Dynamic range, limit of detection, and sensitivity 
Calibration curves of DMDS in swine blood were initially evaluated in the range 
of 0.02-200 µM. Both linear and log-log regression models were used over multiple 
calibration ranges to analyze the calibration behavior of DMDS. Both visual inspection and 
GoF parameters confirmed that a log-log regression model was the best fit model for 
DMDS calibration. This observation matched the calibration behavior of DMTS, which is 
structurally similar to DMDS (i.e., the only difference between DMDS and DMTS is a 
single sulfur atom) [17]. Once the calibration model was confirmed and the dynamic range 


















IS-spiked (2 µM) blood (m/z = 100)
IS-spiked (2 µM) blood (m/z = 82)
Non-spiked blood (m/z = 100)




was set, the lowest two calibrators (i.e., 0.02 and 0.05 µM), fell outside of the linear range. 
Therefore, the dynamic range for DMDS was 0.1 to 200 µM using a log-log regression 
model.  
Table 3.3 shows the consistency of three separate calibration curves of DMDS 
prepared on three consecutive days. All three calibration curves showed consistent slopes 
(i.e., mean mblood = 1.11, with a standard deviation of 0.02), intercepts (i.e., average bblood 
= 0.32, with a standard deviation of 0.04), 2  The PRA 
r 
the calibration range [108]. 
 
Table 3.3: Calibration curve equations and goodness-of-fit analysis. 
Day Equation PRA R2 
Day-1 log y = 1.13 log x  0.36 91.4 0.9984 
Day-2 log y = 1.11 log x  0.29 90.5 0.9982 
Day-3 log y = 1.09 log x  0.32 92.5 0.9987 
 
The current method produced an excellent LOD of 30 nM. This high sensitivity is 
important to detect low level exposure to DMDS, in turn helping to identify the extent of 
community exposure in any unwanted or accidental release of DMDS, such as the mass 
DMDS exposure event in Florida in 2016 [127]. 
 
3.4.3. Accuracy and Precision 
Three QCs (0.35, 7.5 and 75 µM) were analyzed in quintuplicate on three separate 
days to evaluate the accuracy and precision of the method. The experiment was performed 
on three different days over a period of five calendar days and the results were evaluated 
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following FDA method validation guidelines [137]. Although DMDS is very unstable in 
blood, excellent intraassay accuracy (100 ± 8-14%) and precision (<5% RSD), and 
interassay accuracy (100 ± 11%) and precision (<6% RSD) were observed, as shown in 
Table 3.4.  
 




 Intraassay  Interassay 
 Accuracy (%)a  Precision (%RSD)a  Accuracy 
(%)b 
Precision 







0.35  100±12.8 100±8.6 100±4.0  3.4 4.5 4.2  100±8.5 5.2 
7.5  100±12.8 100±6.4 100±12.8  0.9 3.9 4.0  100±10.6 4.2 
75  100±12.9 100±6.9 100±13.3  1.3 3.6 4.2  100±11.0 4.2 
a QCs (n = 5). Accuracy is 
measured as the percent difference of the calculated and nominal concentration of QCs, 
whereas precision is calculated as the %RSD of the calculated concentration of the QCs. 
bAggregate of three days of QC method validation (n = 15) over a period of five calendar 
days. Both accuracy and precision represent the maximum deviation from the nominal 
concentration of the QCs. 
 
The excellent accuracy and precision were a function of the ability of the IS to 
correct for several potential errors, inconsistent recovery, and correction for matrix effect. 
Acid denaturation of the blood also helped provide consistency by minimizing DMDS 
degradation and potential protein binding.  
 
3.4.4. Matrix effect and recovery 
The matrix effect was assessed by constructing two DMDS calibration curves in DI 
water and blood, and comparing the slopes (i.e., mblood/maq). Both non-IS-corrected 
(abundance vs. concentration) and IS-corrected (signal ratio vs. concentration) calibration 
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curves were evaluated to determine the importance of the IS. The ratio of slopes obtained 
from non-IS-corrected samples was 0.85, indicating a minor DMDS-blood matrix 
interaction. The minor signal suppression caused by the matrix was minimized when IS 
was incorporated, producing an IS-corrected slope ratio of 0.95. 
The recoveries of DMDS in swine blood for low, medium, and high QCs were 98, 
95, and 86%, respectively. The obtained recoveries of DMDS were very promising, 
considering its tendency to undergo rapid enzymatic degradation and evaporative loss in 
blood. While the high QC recovery was <90%, the IS readily corrected for this signal loss 
(as mentioned in the matrix effect), producing an IS-corrected signal recovery of 98%. 
 
3.4.5. DMDS storage stability 
The short and long-term stability of DMDS were evaluated under multiple storage 
conditions. The bench-top and autosampler storage stabilities of DMDS were evaluated 
using high and low QCs. For the bench-top stability experiment, DMDS was very unstable 
in spiked non-denatured blood, even after 2 h, where the signal recoveries for the low and 
high QCs were only 7.26 and 11.13% of the original signal, respectively. DMDS was 
undetectable for the low and high QCs at 5 and 10 h, respectively. For autosampler stability, 
for 5 and 10 h for the low and high 
QCs, respectively. While DMDS was considered unstable after 5-10 h on the autosampler, 
IS-corrected signals for both QCs were stable on the autosampler over the 24-h time period 
tested. The freeze-thaw (FT) stability of DMDS was tested over four FT cycles. The DMDS 
QCs showed gradual degradation of DMDS signals with each FT cycle for all three 
methods of preparation (Table 3.2). Maximum degradation was observed for non-
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denatured and non-flash-frozen samples, producing only about 40% of the initial signal 
after the first FT cycle. DMDS spiked into acid-denatured blood followed by flash-freezing 
showed less degradation (about 70% signal recovery after first FT cycle), but DMDS was 
still considered unstable. This quick degradation was expected because DMDS showed 
rapid enzymatic degradation in non-denatured blood. Although both acid-denaturation and 
flash-freezing helped to minimize DMDS degradation for two sets of flash-frozen samples, 
the DMDS was still considered unstable during the FT process. Incomplete recoveries of 
DMDS in acid-denatured samples could be attributed to the evaporative loss during 
thawing process. Therefore, freezing and thawing of DMDS-spiked blood samples should 
be avoided and addition of IS prior to freezing is essential. 
The long-term stability of DMDS was evaluated for up to 90 days for both low and 
high QCs, with IS, at 4, -30 and -80 °C. Two sets of frozen samples (i.e., the samples to be 
stored at -30 and -80 -  
 freezing. Similar to the FT stability 
findings above, the flash frozen samples were much more stable than samples frozen 
unassisted. Specifically, DMDS signals recovered from unassisted freezing produced 
signals <90% of the original signal after only one day of storage. Figure 3.2 shows the 
results from the long-term stability experiment, considering only the flash frozen samples 
for storage at -30 and -80 °C. The IS-corrected signals for DMDS were consistent at all 
three temperature conditions until Day 30. After Day 30, samples stored at 4 °C showed 
visible changes (i.e., all started to coagulate and turn into non-uniform mixtures), and the 
IS-corrected signal loss was drastic (only 45% signal recovery at Day 30 compared with 
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-30 and -80 °C did not change in appearance and IS-corrected 






























Figure 3.2. Evaluation of DMDS stability studies (with IS correction) during storage at 4, 
-30 and -80 °C, over 90-day period tested. 
 
Based on aggregate storage stability results, three major observations can be drawn: 
1) addition of IS before storing the sample is vital to obtain accurate DMDS concentrations 
following storage, 2) acid-denaturation followed by flash-freezing prior to storing the 
sample in the freezer helps minimize loss of DMDS, and 3) storage temperatures from 4 to 
-80 °C can be used to store blood samples for DMDS analysis for up to one month, but 
beyond that, it is recommended samples are stored at -30 or -80 °C. Overall, the best 
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the blood, addition of IS (DMDS-d6), flash-freezing of the sample and storage in a -80 °C 
freezer. 
 
3.4.6. Analysis of DMDS in treated animals 
According to the United States Environmental Protection Agency, the DMDS 
vapor concentration of concern for human health is 55 ppb, based on a 24-hr acute rat 
inhalation study [138]. Considering this level of concern and that humans can smell very 
low levels of DMDS (7-12 ppb), humans can typically avoid high levels of inhalation 
exposure [127]. When considering the toxicity of DMDS in humans, there is very little 
information available. While there is no published study that describes the blood 
concentration of DMDS that is associated with DMDS toxicity, one report was published 
from China where a fatal volatile sulfur compound poisoning occurred at a bamboo pulp 
mill and the autopsy report revealed the presence of 3.1 mg/mL (32.9 mM) DMDS [136]. 
The DHS-GC-MS method reported here was used to analyze the blood concentration of 
DMDS generated from DMTS-treated pigs. Representative chromatograms were obtained 
(m/z of 94) by analyzing the blood from DMTS-treated and untreated pigs are shown in 
Figure 3.3. DMDS eluted at 2.70 min with no interfering peaks at the retention time of 
DMDS in untreated pigs and detectable levels of DMDS ranged from 0.1  11 . 
Therefore, the maximum concentration of DMDS in the swine blood was 3,000 times lower 
than the blood concentration of the victim of the volatile sulfur compound poisoning 




Figure 3.3. Representative GC MS chromatograms of DMDS (10.46 µM) in the blood of 
DMTS-treated and untreated swine (m/z of 94). 
 
To further evaluate how close DMDS production from DMTS treatment 
approaches toxic levels, we converted the known rat LD50 value for acute oral exposure to 
DMDS (i.e., 190 mg/kg [138]) to a swine LD50 (33.7 mg/kg) using standard human 
equivalent dose calculations [139]. Considering the swine were administered 10 mg/kg of 
DMTS and we have experimentally observed about 50% conversion of DMTS to DMDS 
in swine blood,  mg/kg. Therefore, based on these 
assumptions and assuming equivalency of the oral and IM LD50 values, the estimated IM 
dose of DMDS in this study is about 6.7 times lower than the LD50 of DMDS. Because 
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large assumptions are necessary to complete this comparison since there is a paucity of 




A simple, highly sensitive, environment friendly and cost-effective DHS-GC-MS 
method was developed for the rapid analysis of DMDS in blood. This method is the first 
validated method for analysis of DMDS in a biological matrix that can investigate DMDS 
toxicity and the severity of community exposure during DMDS fumigation. This method 
does not require any toxic organic solvents for extraction and can detect and quantify as 
low as 30 and 100 nM of DMDS, respectively. Our recommended storage procedure allows 
accurate and reproducible analysis of DMDS blood samples up to 90 days following 
collection. The availability of this method now allows quantification of DMDS blood 
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Chapter 4. Analysis of aminotetrazole cobinamide, a next-generation antidote for 
cyanide, hydrogen sulfide and methanethiol poisoning, in swine plasma by liquid 
chromatography-tandem mass spectrometry 
 
4.1. Abstract 
Cyanide and reduced sulfur compounds, especially hydrogen sulfide and 
methanethiol, are common toxic inhalation agents that inhibit mitochondrial cytochrome c 
oxidase and result in cellular hypoxia, cytotoxic anoxia, apnea, respiratory failure, 
cardiovascular collapse, seizure and potentially death. All are occupational gas exposure 
hazards and have the potential to cause mass casualties from industrial accidents or acts of 
terrorism, yet currently FDA-approved antidotes have major limitations, including difficult 
administration in mass-casualty settings. While aminotetrazole cobinamide (CbiAT) has 
recently gained attention because of its efficacy in treating each these metabolic poisons 
and its ability to address limitations of current antidotes, there is no method available for 
the analysis of CbiAT in any biological matrix. Hence, in this study, a simple and rapid 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed 
and validated for the analysis of CbiAT in swine plasma. The method is extremely simple, 
consisting of protein precipitation, separation and drying of the supernatant, reconstitution 
in an aqueous solvent, and LC-MS/
with a wide dynamic range (2  - and intraassay accuracies (100±12% and 
100±19%, respectively) were acceptable and the precision (<12% and <9% relative 
standard deviation, respectively) was good. The developed method was used to analyze 
CbiAT from treated swine and the preliminary pharmacokinetic parameters showed 
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impressive antidotal behavior, most notably quick absorption and distribution (Cmax and 
tmax of 44.7 µM and 4 h, respectively) and slow elimination (t1/2 = 23.7 h). This simple and 
rapid method can be used to facilitate the development of CbiAT as a therapeutic against 
toxic cyanide, hydrogen sulfide and methanethiol exposure.  
 
4.2. Introduction 
Exposure to cyanide (CN  and HCN, inclusively represented as CN) and reduced 
sulfur compounds (RSCs, i.e., hydrogen sulfide (H2S) and methanethiol (MT)) occurs in a 
variety of settings, including occupational exposure and from acts of terrorism [22, 55, 93]. 
Although CN is extremely poisonous (e.g., rat LC50, 5- [140, 
141] and 50 mg can be lethal to humans [142]), it is still widely used in chemical industries 
to produce synthetic fibers and polymers, and for gold mining, electrolysis, electroplating, 
and pest control [17, 143]. Annual global production of CN is over 5.2 billion pounds [55]. 
Like CN, RSCs are extremely poisonous, with LC50 values in rats for 5-min of inhalation 
exposure of 444 and 675 ppm for H2S and MT, respectively [71]. These compounds are 
commonly found in oil and gas industries, wastewater treatment facilities, plastic and paper 
mill industries, as well as in hot springs and volcanoes [68, 69].  
CN, H2S and MT each have similar mechanisms of toxicity. Once absorbed into 
the blood stream, these compounds inhibit mitochondrial cytochrome c oxidase, thereby 
terminating oxidative phosphorylation, interrupting the electron transport chain, reducing 
ATP production, and causing hyperlactatemia and metabolic acidosis [17, 20-22]. As a 
result, the common toxic outcomes include hypoxia, cytotoxic anoxia, cardiac arrhythmias, 
bronchospasm, respiratory paralysis, coma, and death [22, 36, 136]. These compounds 
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inhibit multiple other enzymes, including succinic dehydrogenase, carbonic anhydrase, and 
superoxide dismutase [26, 27]. Because the mechanisms of toxicity are similar, victims of 
CN, H2S and MT poisoning show essentially identical clinical symptoms. Therefore, it is 
desired to develop a single antidote that is effective against all of these poisons which can 
be administered by oral or intramuscular (IM) route, allowing more feasible administration 
during mass-exposure scenarios. 
There are no currently Food and Drug Administration (FDA)-approved antidotes 
for either H2S or MT [22, 68] while there are effective FDA-approved antidotes for CN 
poisoning (i.e., hydroxocobalamin, as Cyanokit® and sodium nitrite/sodium thiosulfate, as 
Nithiodote®), each has major limitations [17]. Both the Cyanokit® and Nithiodote® require 
large doses and slow intravenous infusion, which necessitates trained medical personnel 
and specialized equipment [55, 56]. These antidotes are expensive and a second dose is 
sometimes required based on the severity of poisoning [44, 57]. These disadvantages limit 
their applicability in the event of an industrial accident, structural fire, or terrorist attack, 
where rapid administration of antidote in a short period of time is necessary [57, 76]. 
Patients may even require special medical attention for antidote-induced adverse effects, 
such as dizziness, blurred vision, confusion, vomiting, cardiac arrythmia, tachycardia, 
hypotension, hypertension, and methemoglobinemia [57-59]. The limitations of CN 
antidotes have necessitated the search for a more effective countermeasure. 
To address the absence or limitations of current metabolic poison antidotes, 
aminotetrazole cobinamide (CbiAT) was developed as a prodrug of cobinamide (Cbi). 
CbiAT is effective for treating multiple metabolic poisons and can be IM administered. 
[22, 68, 95]. While Cbi is similar to cobalamin (i.e., it is the penultimate precursor in the 
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biosynthesis of hydroxocobalamin [22], it can bind two ligands versus one for cobalamin. 
Moreover, Cbi does not suffer from the negative trans effect of dimethyl-benzimidazole 
group on the binding site (i.e., coordinating to the central cobalt atom in the lower axial 
position) [55, 96]. As a result, depending on the formulation, a 3-10 times higher dose of 
hydroxocobalamin is required to produce the same therapeutic effect of Cbi [56, 91]. 
Additionally, in aqueous solution, Cbi, as aquohydroxocobinamide (AHCbi), shows five 
times more water solubility than hydroxocobalamin [96], allowing a smaller volume to be 
administered to produce the desired therapeutic effect. Because of its effectiveness as an 
antidote for metabolic poisons, Cbi has recently gained attention as a potent next generation 
antidote for CN, H2S and MT poisoning [22, 90-95]. While Cbi is a promising antidote, 
some formulations have presented challenges. For example, AHCbi is not a good drug 
candidate for IM injection because it interacts with the macromolecules at the injection 
site, which limits its rate of absorption [97]. To address these challenges, multiple 
formulations have been evaluated [22, 144] and CbiAT was found to produce the most 
advantageous characteristics for treatment of metabolic poisons, allowing for quick 
absorption after IM administration, while retaining effective binding of CN, H2S and MT 
[22].  
In spite of the potential advantages of CbiAT over other countermeasures, there is 
no currently available analytical approach for the quantification of CbiAT in any biological 
matrix. Therefore, the objective of this study was to develop and validate an effective liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) technique for the analysis of 
CbiAT in plasma to allow for further development of CbiAT as a next-generation antidote 




4.3.1. Reagents and standards 
Sodium hydroxide (NaOH), ammonium hydroxide (NH4OH, 29% by weight), 
acetonitrile (ACN) and sodium cyanide (NaCN) were obtained from Fisher Scientific (Fair 
Lawn, NJ, USA). Ammonium formate and 5-amino-1H-tetrazole monohydrate (ATM) 
were purchased from Fluka Analytical (Sigma-Aldrich, St. Louis, MO, USA) and Alfa 
Aesar (Tewksbury, MA, USA), respectively. Aquohydroxocobinamide (AHCbi) was 
provided by Dr. Gerry R. Boss, MD, Department of Medicine, University of California, 
San Diego, La Jolla, CA 92093, USA, following synthesis [96]. Deionized water (DI water) 
-cm using a Lab Pro polishing unit from Labconco 
Corporation (Kansas City, KS, USA). All reagents used in this experiment were of high-
performance liquid chromatography (HPLC) grade, unless otherwise noted. 
Stock solutions of AHCbi (10 mM prepared in an amber vial) and ATM (20 mM, 
pH = 7.4) were prepared in DI water and stored at 4 °C. Calibration and quality control 
(QC) standards of CbiAT were prepared by mixing AHCbi and ATM at a 1:1 molar ratio, 
leaving on the benchtop for 10 min, diluting to the desired concentration via serial dilutions 
in DI water, and spiking the aqueous CbiAT into swine plasma (1:9 ratio). CbiAT spiked 
plasma mixtures were then mixed well at 3,000 rpm (252 × g) for 10 s before sample 
preparation. 
For protein denaturation, 10% NH4OH in ACN solution was used. This solution 
was prepared by transferring 7.86 mL of NH4OH (29% by weight) in a 100-mL volumetric 
flask, followed by addition of ACN to the 100-mL mark, capping tightly, mixing well and 
storing at room temperature for future use. 
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4.3.2 Biological samples 
For analytical method development and validation, swine plasma (with heparin as 
anticoagulant) was obtained from Pel-Freez Biologicals (Rogers, AR, USA) and stored at 
T for drug development 
studies, the method was utilized to analyze swine plasma from a CbiAT pharmacokinetic 
study performed at University of Colorado Anschutz Medical Campus (Aurora, CO, USA). 
This study was utional Animal Care and 
Use Committee (IACUC) and complied with the regulations and guidelines of the Animal 
Welfare Act and the American Association for Accreditation of Laboratory Animal Care. 
One female Yorkshire cross swine, weighing about 50 kg, was used for this study. 
Anesthesia was induced with 10 mg/kg ketamine (MWI, Boise, ID) and sedation 
maintained with 1-3% isoflurane (MWI, Boise, ID) with an FiO2 of 21%. The animal was 
intubated with an 8.0 mm cuffed endotracheal tube (Teleflex, Morrisville, NC). Heart rate, 
arterial blood pressure, end tidal CO2, oxygen saturation, and body temperature were 
monitored continuously throughout the study. The animal was treated intramuscularly with 
a dose of 75 mg/kg CbiAT, and blood was collected at 0 (baseline), 4, 24, 48, 72, 96, and 
168 h post-injection. Collected blood was placed in lithium heparin tubes and centrifuged. 
Plasma was then transferred to 2-mL clean centrifuge tubes and shipped on ice (overnight) 
to South Dakota State University (Brookings, SD, USA) for the analysis. Upon receipt, the 
samples were stored at -80 °C until analysis was performed with the validated CbiAT 




4.3.3 Sample preparation for LC-MS/MS analysis 
CbiAT- as first denatured by adding 700 µL of 10% 
NH4OH in ACN solution (see Section 2.1 for detailed preparation procedure). The mixture 
was then vortexed for 10 s at 3,000 rpm (252 × g) and cold centrifuged (at 8 °C) for 20 min 
at 14,500 rpm (16,454 × g). Afterwards, 700 µL of the supernatant was transferred into a 
4-mL glass vial and dried with inert nitrogen gas for about 30 min at room temperature. 
The completely dried sample was then reconstituted with 100 µL of 10% aqueous ACN 
solution, vortexed briefly (~10 
tetrafluoropolyethylene membrane syringe filter, and the filtrate (100 µL) was transferred 
into a glass insert assembled in a 2-mL HPLC vial for LC-MS/MS analysis. 
 
4.3.4. LC-MS/MS analysis 
Liquid chromatographic analysis of CbiAT was conducted on a Shimadzu HPLC 
system (LC- -RP 
column (50 mm length × 2 mm internal diameter, 4 µm particle size and 80 Å pore size) 
was used at ambient temperature for chromatographic separation. Ammonium formate (5 
mM) in 10% ACN (mobile phase A) and ammonium formate (5 mM) in 90% ACN (mobile 
phase B) were used to separate CbiAT at a flow rate of 0.5 mL/min with a gradient of 0% 
B increased linearly to 100% over 0.5 min, held constant for 1.5 min, decreased to 0% B 
over 0.5 min, and held constant for 0.5 min to equilibrate between injections. A cooled 
autosampler (15 °C) was used to store prepared samples, and the injection volume was set 
to 30 µL. Mass spectroscopic analysis of CbiAT was performed by a tandem mass 
spectrometer (AB Sciex QTRAP 5500 MS, Framingham, MA, USA) using positive 
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polarity electrospray ionization (ESI). To identify abundant fragments, a standard solution 
of CbiAT was directly infused into mas After 
infusion of CbiAT into the ESI, molecular ion (in the form of CbiAT dihydrate) of m/z 
1196.5 was identified ([M + H]+). Multiple reaction monitoring (MRM) transitions were 
identified based on most abundant product ions of CbiAT, and other parameters were 
optimized and are outlined in Table 4.1.  
 
Table 4.1: MRM transitions, and optimized declustering potentials (DPs), entrance 
potentials (EPs), collision energies (CEs), and collision cell exit potentials (CXPs) for 

















1196.5 1028.6 100 177.47 3.44 57.97 18.23 
CbiAT 
(Identification) 
1196.5 989.7 100 159.11 7.16 76.49 12.85 
 
For the method, CbiAT was analyzed in MRM mode and the data acquisition was 
performed using Analyst software (Applied Biosystems, Version 1.6.3). For the detection 
of CbiAT, nitrogen at a pressure of 40 psi was used as both curtain and nebulization gas. 
The ion spray voltage was set at 5,500 V with a source temperature of 500 °C. Nebulizer 
(GS1) and heater (GS2) gas pressures were 40 and 60 psi, respectively.  
Carryover is a common problem with the analysis of Cbi species because it has a 
tendency to bind with the column and other LC-MS/MS components, including the 
autosampler syringe  [56, 145]. A comprehensive cleaning protocol was devised by Dzisam 
et al. [56] to remove Cbi from LC-MS/MS systems. While this protocol eliminated 
carryover, it consisted of a large number of relatively complex steps, including separate 
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washing of (1) the LC system and (2) the column. According to this protocol, the LC system 
wash included three steps: (a) rinsing the system with DI water followed by aqueous ACN 
solutions (5% and 10%), (b) multiple injection of a diluted cyanide solution (100 µM, n = 
50), and (c) washing with aqueous ACN solutions (5% and 10%). The column wash 
required even longer times and three additional steps: (a) overnight washing with a mixture 
of Na2SO4 (1 mM aqueous) and ACN (1:10 ratio), (b) washing of residual Na2SO4 from 
the column for 4 h with 5% aqueous ACN solution followed by 2 h wash with 10% aqueous 
ACN solution, and (c) multiple injection of a dilute cyanide solution (100 µM, n=70).  
Unlike other species of Cbi, CbiAT complex does not bind strongly with the LC-
MS/MS components. Therefore, we extensively modified the cleaning protocol and 
utilized ATM as a much less-toxic substitute for cyanide. The revised protocol consisted 
of the following two simple steps: (a) rinsing of the LC system (including the column) via 
much fewer injections of 200 µM aqueous ATM (n = 5) after analysis of each set of CbiAT, 
and (b) much fewer injection of aqueous NaCN (100 µM in 10 mM NaOH, n = 10) without 
column and periodically checking for the presence of Cbi(CN)2 using the method 
developed by Dzisam et al. [56]. During CbiAT analysis, 200 µL of 90% aqueous ACN 
solution was used to rinse the autosampler syringe between injections. 
 
4.3.5. Calibration, quantification, and limit of detection 
The developed method was validated by following the FDA bioanalytical method 
validation guidelines [146]. To evaluate the calibration behavior of CbiAT, calibration 
standards (0.5, 1, 2, 5, 10, 20, 50, 100, 200, and 500 µM) were prepared in swine plasma 
in triplicate from the CbiAT stock solution (5 mM). Following analysis, the average peak 
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areas of CbiAT were plotted as a function of plasma CbiAT concentrations. Both weighted 
(1/x and 1/x2) and unweighted linear (y = mx + c) and unweighted log-log (log y = m log 
x + log c) regression models were constructed to evaluate the best fit model for CbiAT 
analysis. Percent residual accuracy (PRA) was considered and emphasized over the 
frequently used coefficient of determination (R2) to quantify the goodness-of-fit (GoF) of 
the calibration models as the current method used a geometric series of concentrations for 
calibration curve preparation. When calibration curves span 2-3 orders of magnitude, R2 is 
significantly limited, typically misrepresenting the GoF throughout the calibration range. 
considered indicative of a good fit [17, 36, 108].  
The upper and lower limit of quantification (ULOQ and LLOQ, respectively) were 
set based on the calibrator precision of <15% relative standard deviation (RSD), and an 
accuracy of 100±20% of the nominal calibrator concentration back-calculated from the 
calibration curve. To calculate the limit of detection (LOD), multiple concentrations of 
CbiAT were prepared in plasma below the LLOQ and analyzed. The LOD was defined as 
the lowest CbiAT concentration which reproducibly produced a signal-to-noise (S/N) ratio 
of at least 3. Blank samples were analyzed to determine the noise as peak-to-peak noise 
over the elution time of CbiAT. 
 
4.3.6. Accuracy and precision 
To calculate the intra- and interassay accuracies and precisions of the method, 
calibration 
5 each) were prepared in swine plasma and analyzed in parallel each day for three days 
(within five calendar days). The intraassay accuracy and precision were determined from 
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the QCs on the interassay accuracy and precision were 
calculated by comparing QCs over three separate days. The selection criteria for accuracy 
and precision were set at <15% RSD and 100±20%, respectively. 
 
4.3.7. Matrix effect and recovery 
To determine the matrix effect, calibration curves were prepared by spiking CbiAT 
in aqueous solution (where plasma was replaced by DI water during sample preparation) 
and plasma. The slopes of the resulting calibration curves were compared. A slope ratio 
(i.e., mplasma/maqueous) of <1 and >1 indicate plasma matrix suppression and enhancement 
effects, respectively. The recovery of CbiAT was calculated by comparing the signals of 
 concentration of QCs 
spiked in aqueous solution. Recovery was determined by dividing the average peak area of 
CbiAT in plasma by the average peak area of the equivalent concentration aqueous QC and 
multiplying by 100%. 
 
4.3.8. Stability 
The short- and long-term stabilities of CbiAT were evaluated by analyzing 
triplicates of plasma spiked at low (7.5 µM) and high (150 µM) QC concentrations stored 
at different conditions for multiple time periods. CbiAT was considered stable in plasma if 
the signal from a stability standard was within ±10% of the initial (time 0) signal. As a part 
of short-term stability study, bench-top and autosampler stabilities were assessed for 24 h, 
and freeze-thaw (FT) stability was performed for four FT cycles. For bench-top stability, 
CbiAT spiked non-denatured plasma for both QCs were left on the benchtop for 0, 1, 2, 5, 
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10 and 24 h at room temperature before analysis. To evaluate the autosampler stability, the 
prepared QCs were placed in the autosampler of the LC at 15 °C and were analyzed at 0, 
1, 2, 5, 10 and 24 h. FT stability samples were prepared in two different ways before storing 
the CbiAT spiked non-denatured plasma samples at -80 °C: (a) unassisted freezing, and (b) 
flash-freezing in liquid nitrogen. Five sets of QC samples were prepared in triplicate, where 
) were kept at -80 °C. After 24 h for 1 FT cycle, all stored samples were 
thawed at room temperature by leaving the vials undisturbed on the countertop for about 
10 min. After fully thawing the samples, one set of QCs (for both unassisted and flash 
freezing) were analyzed following the necessary sample preparation steps, while the rest 
three sets were placed back at -80 °C. This procedure was repeated three more times to 
evaluate four FT cycles. 
For evaluation of the long-term stability of CbiAT, the QC samples were prepared 
as with the FT stability study: (a) unassisted freezing, and (b) flash-freezing. These samples 
were analyzed after 0, 1, 2, 5, 15, and 30 days. For unassisted freezing, the CbiAT-spiked 
plasma samples were stored at 4, -20 and -80 °C, whereas flash frozen samples were first 
frozen in liquid nitrogen before storing in -20 and -80 °C freezers. Both QCs were prepared 
in bulk to minimize sample-to-sample variation. To correct for day-to-day instrument 
sensitivity, fresh QCs were prepared each day in triplicate. The average peak area signal 
ratio of the QC from the stability sample to the QC prepared fresh on the same day was 





4.4. Results and Discussion 
4.4.1. LC-MS/MS analysis of CbiAT 
The LC-MS/MS method reported here is the first ever published technique for 
CbiAT analysis from any biological matrix. It features rapid and simple sample preparation 
of a small volume of plasma (100 µL), consisting of plasma protein denaturing (with 10% 
NH4OH in ACN), centrifugation (16,454 × g), transfer and drying of the supernatant (under 
inert nitrogen), reconstitution (10% aqueous ACN), and LC-MS/MS analysis. The overall 
sample preparation time was less than 1 h, with the chromatographic analysis time of only 
3 min allowing an estimated 480 samples to be analyzed over a 24-h period. Figure 4.1 
shows the mass spectrum of CbiAT produced by ESI(+)-MS with the CbiAT molecular ion 
structure ([M + H]+, m/z = 1196.5) and its abundant ions inset. Transitions 1196.5  
1028.6 and 1196.5  989.7 were used for quantification and identification, respectively. 
Figure 4.2 shows chromatograms of the quantification (1196.5/1028.6 m/z) and 
identification (1196.5/989.7 m/z) transitions from analysis of CbiAT-spiked and non-
spiked plasma. The CbiAT peak eluted at 1.5 min. The selectivity of CbiAT was excellent 
as there was no significant peak, aside from CbiAT, in the blank or spiked samples eluting 
throughout the chromatographic run time. The CbiAT peak was quite symmetrical above 
a flat baseline, with an asymmetry factor (As) of <1.3 and a tailing factor (Tf) of 1.15. The 
Tf and As indicate only slight tailing, but both values were well within generally accepted 
ranges (i.e., As <2.0 and Tf <2.0).  
The cleaning protocol devised for CbiAT was rapid (<1 h) and easy to adopt 
compared with the protocol proposed by Dzisam et al. [56], which required over 24-h and 
either two LC systems or utilizing a single LC-MS/MS system for over 24-h. Moreover, 
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the use of ATM decreased the volume of cyanide solution necessary to clean and check for 
residual Cbi in the LC-MS/MS. 
 
Figure 4.1. ESI(+) mass spectra of CbiAT with identification of the abundant ions. Insets: 
Structure of CbiAT with abundant fragments indicated. AT represents 5-amino-1H-
tetrazole. 
 




































Figure 4.2. LC-MS-MS chromatogram of CbiAT-spiked plasma (20 µM) and non-spiked 
plasma. Transitions 1196.5/1028.6 and 1196.5/989.7 represent quantification and 
identification MRM, respectively. 
 
4.4.2. Dynamic range and limit of detection 
The current is 
similar to the LODs of previous cyanoCbi [56] and total Cbi [143] methods, which was 0.2 
µM for both approaches. The low LOD is important because the method can be used to 
detect the presence of low levels of CbiAT for drug-development studies.  
For dynamic range determination, calibration curves were evaluated over the 
concentration range of 0.5   of 


















CbiAT-spiked plasma (20 µM)  
(quantification MRM)
CbiAT-spiked plasma (20 µM) 
(identification MRM)
Non-spiked plasma (quantification MRM)
Non-spiked plasma (identification MRM)
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residuals for both linear and log-log regression models, we found 0
outside the calibration range and that a log-log regression model produced the best fit for 
the calibration data
(ULOQ). This dynamic range is useful for drug-development studies where analysis of a 
wide concentration range is necessary. To test the consistency of the calibration, three 
calibration curves were prepared on three consecutive days. Consistent slopes (i.e., mean 
mplasma = 1.66 with a standard deviation of 0.02) and intercepts (i.e., mean mplasma = 1.47 
with a standard deviation of 0.07) were found and all calibration curves showed acceptable 
2 , indicating an excellent fit of all the data over the 
calibration range. Table 4.2 shows the consistency of CbiAT calibration curves and 
goodness-of-fit analysis over 3 days.  
 
Table 4.2: Calibration curve equations prepared on three consecutive days with related 
goodness-of-fit parameters. 
Day Calibration equation PRA (%) R2 
Day-1 log y = 1.64 log x + 1.40 94.2 0.9955 
Day-2 log y = 1.65 log x + 1.56 93.8 0.9943 
Day-3 log y = 1.69 log x + 1.45 93.4 0.9938 
 
4.4.3. Accuracy and Precision 
Quintuplicate analysis of three QCs (7.5, 35, as performed on three 
separate days to determine the accuracy and precision of the proposed method. As shown 
in Table 4.3, inter- and intraassay accuracies (100±12% and 100±19%, respectively) and 
precisions (<12% and <9% RSD, respectively) were considered acceptable, according to 
the FDA method validation guidelines [146]. While future addition of an internal standard 
(IS) may theoretically help to improve the intraassay accuracy (i.e., it was close to the 
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selection criteria limit of 100±20%), an IS would likely be difficult to synthesize and may 
compete for ligands bound to the analyte. Therefore, it is likely that an IS structurally 
similar to CbiAT would be problematic. 
 
Table 4.3: The intra- and interassay accuracies and precisions for analysis of CbiAT from 
spiked swine plasma. 
Conc 
(µM) 
 Intraassay  Interassay 













7.5            
35            
150            
a  
bAggregate of three days of QC method validation (n = 15). 
 
4.4.4. Matrix effect, recovery, and storage stability 
The matrix effect was determined by comparing the slopes of plasma and aqueous 
calibration curves (i.e., mplasma/maqueous). The ratio of the slopes obtained was 1.04, 
indicating essentially no matrix effect occurs from plasma. The percent recoveries for 
CbiAT in swine plasma for low, medium, and high QCs were 38, 33, and 32%, 
respectively. This low recovery is likely due to low extraction of CbiAT from plasma with 
10% NH4OH in ACN solution. While the recovery was low, it was very consistent and did 
not affect the ability to accurately analyze CbiAT.  
For the bench-top stability study, CbiAT was unstable in spiked non-denatured 
plasma at room temperature. Even after 1 h, the signal recoveries for the low and high QCs 
e, 





samples, the unassisted freezing samples showed about 30% signal loss after one FT cycle 
and then minimal loss after each subsequent FT cycle. This initial loss of CbiAT signal is 
likely because of the quick interaction of Cbi with other strong ligands (e.g., carbon 
monoxide (CO), cyanide (CN-) or nitrite (NO2-)) available in plasma or interaction with 
plasma proteins, which was effectively minimized using liquid nitrogen immediate after 
spiking the CbiAT in plasma. The long-term stability of CbiAT was evaluated for 30 days 
and the stored samples were analyzed after 0, 1, 2, 5, 15, and 30 days. CbiAT was stable at 
both -20 and -80 °C for at least 30 days when the samples were flash-frozen prior to storage. 
 after 24 h and there was 
a visual change in appearance after Day-5. Unassisted freezing samples stored at -20 and -
80 °C showed about 60 and 48% degradation, respectively, after 30 days of storage.  
Based on the overall results from the evaluation of storage stability, the following 
major conclusions can be drawn: 1) flash-freezing prior to storage is vital to limit initial 
loss of CbiAT, 2) CbiAT is stable for at least 30 days in plasma when flash frozen and 
stored at -20 or -80 °C, 3) prepared samples placed in the autosampler are stable at least 24 
h, and 4) flash frozen samples are stable for at least four FT cycles. 
 
4.4.5. Method application and pharmacokinetics 
The validated LC-MS/MS method was applied to the analysis of swine plasma 
obtained from a CbiAT pharmacokinetic study. Figure 4.3 shows the chromatograms of 
plasma of swine treated with CbiAT and untreated swine plasma collected prior to 
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treatment. The CbiAT peak was observed at 1.5 min in the treated plasma samples, whereas 
the plasma sample prepared from non-treated swine showed no peak at the retention time 
of CbiAT. The outcome confirmed the selectivity and the applicability of the method to 
analyze CbiAT-treated animal samples. 
A preliminary pharmacokinetic profile of CbiAT (75 mg/kg IM) in swine (n=1) is 
presented in Figure 4.4. As CbiAT is a new drug candidate and no prior animal experiment 
was performed using CbiAT, the current animal experiment considered a comparatively 
long time interval (up to 168 h) to evaluate the pharmacokinetics of IM-administered 
CbiAT. Although preliminary, the toxicokinetic behavior of CbiAT was best described by 
a one-compartment model [147], with a Cmax and tmax of 44.7 µM and 4 h, respectively, 
indicating quick CbiAT distribution and availability throughout the body. It should be 
noted that time intervals prior to 4-h must be evaluated to confirm one-compartment 
behavior of CbiAT. The elimination was somewhat slow, with a t1/2 of 23.7 h, and the area 
under the curve was large (i.e., AUC = 855.01 µM·h) showing that a large amount of 
CbiAT is available at this dose. The quick distribution and slow elimination of CbiAT from 
IM administration is promising, in that it should allow both quick antidotal efficacy 
following treatment and longer duration of treatment in situations where multiple 
exposures or continuous exposure occurs. The favorable pharmacokinetic profile of CbiAT 
administered via IM injection should allow relatively simple on-site self-treatment or 
treatment by untrained personnel. Overall, this preliminary pharmacokinetic experiment 
revealed impressive pharmacokinetic behavior of CbiAT, most notably a quick onset of 
action and slow elimination, but this experiment must be repeated with a much larger n-




Figure 4.3. Representative LC-MS/MS chromatogram at an MRM transition of 
1196.5/1028.6 m/z (CbiAT quantification MRM transition) from the plasma of CbiAT-
treated and untreated (prior to CbiAT treatment) swine. 


















Plasma from non-treated swine




Figure 4.4. Plasma concentration-time behavior of CbiAT following IM administration of 
CbiAT to swine. Error bars represent standard error of the mean (n = 3). Inset: 
Representation of CbiAT elimination constant (KE) by log concentration-time graph. 
 
4.5. Conclusions 
A rapid and simple LC-MS/MS method was developed for the quantification of 
CbiAT in plasma. This method is the first ever validated method for the determination of 
CbiAT in any biological matrix. The applicability of this method was successfully tested 
by analyzing the plasma of swine treated with CbiAT and the preliminary results showed 
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this method and the excellent pharmacokinetic behavior of CbiAT will allow further 
development of CbiAT as a potential countermeasure for CN, H2S and MT poisoning. 
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Chapter 5. Conclusions, Broader Impacts, and Future Works 
 
5.1. Conclusions 
A rapid, cost effective, environmentally friendly, and highly sensitive DHS-GC-
MS method was developed for the analysis of DMTS, a highly promising next generation 
CN antidote, in whole blood. This validated method was successfully applied to establish 
the pharmacokinetic profile of DMTS in animal blood, and the results obtained after 
analyzing DMTS pharmacokinetic study samples were highly promising.  Another DHS-
GC-MS method was developed and validated for the rapid analysis of DMDS in blood. 
This highly sensitive method was used to analyze the level of formation of DMDS 
following DMTS treatment in swine blood. Preliminary pharmacokinetic and toxicokinetic 
parameters of DMDS were also established, which will be helpful for DMTS drug-
development studies. A simple and direct LC-MS/MS method was also developed for the 
quantification of CbiAT, a CN, H2S and MT countermeasure, in swine plasma. The 
applicability of this method was evaluated by analyzing CbiAT treated swine from 
pharmacokinetic study and the preliminary pharmacokinetic parameters of CbiAT in swine 
plasma were very promising for its use as an antidote for these poisons. 
 
5.2. Broader impacts 
Although TIAs are extremely poisonous and can also be lethal, but they all have 
chemical, plastic, and pharmaceutical importance, therefore, most of the incidences and 
fatalities from TIs exposure happened in industrial settings. Hence, research to understand 
their toxicokinetic properties, designing quick detection technologies, development of 
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effective method to determine their level of exposure, and development of effective 
countermeasures are important to understand their behavior and defend against the adverse 
health effects of TIA exposure. The method reported here for the quantification of DMTS 
will allow for further development of DMTS as a promising next-generation antidote for 
CN exposure. In addition, the method developed for DMDS will help to understand the 
effectiveness of DMTS in detoxifying CN and will provide insight into the level of 
community exposure during DMDS fumigation. Furthermore, the method developed and 
reported here for the analysis of CbiAT will help further development of CbiAT as a 
potential antidote for CN, H2S and MT exposure. 
 
5.3. Future work 
Future work should include more evaluation of DMTS effective dose and route of 
treatment based on pharmacokinetic and toxicokinetic profiles before extending the 
experiment its development towards clinical trials. The toxicokinetics of DMDS should be 
better evaluated in toxicological models of DMDS exposure to understand its behavior. As 
with DMTS, pharmacokinetic studies on CbiAT should also be performed in other animal 
models with more statistical significance as part of its development as a TIA antidote. 
Moreover, future work should identify and characterize the level of formation of DMTS 
and CbiAT degradation product(s) in biological matrices as well as in pharmaceutical 
preparations and evaluate their safety profiles. Lastly, the stabilities of DMTS and CbiAT 
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